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The CC3 gene was first identified as a novel tumor suppressor gene of variant small 
cell lung carcinoma (v-SCLC) as its over-expression was found to suppress the 
metastatic potential of v-SCLC cells. Consistent with its proposed function as a tumor 
suppressor gene, the CC3 gene is expressed at low levels in some highly aggressive 
tumor cell lines derived from gastric, SCLC and human hepatocellular carcinoma. 
While the tumor suppressive effects of CC3 had been extensively studied, a recent 
study in prostate cancer showed that increased CC3 expression was associated with 
invasion and metastasis.  These findings suggest that CC3 may have bi-functional 
roles and its mechanism of action may be highly cell-type specific. Hence, it is 
necessary to investigate the role of CC3 in other cancer types in order to understand 
its function in human carcinogenesis.  
 
Colorectal cancer is the third most common cancer expected to occur and the third 
highest expected number of deaths from cancer. To this end, we developed a novel 
CC3 monoclonal antibody for immunohistochemistry. We characterized that CC3 
acts as a tumor suppressor in colorectal cancer, where significant loss of CC3 was 
found in advanced colorectal cancer tissues, more aggressive mucinous sub-types and 
tumors which metastasized to the liver. In normal colon tissues, CC3 was stained 
strongly at the luminal surface of the crypt and negatively stained at the base of the 
crypts. This differential staining is consistent with its hypothesized function as a pro-
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apoptotic protein, where cells are the surface epithelium are committed to cell death 
and cells at base of crypts are rapidly proliferating.  
 
Over-expression of CC3 in colorectal cancer cell lines resulted in reduced cell growth 
and increased apoptosis as shown by various techniques. We show that these were, in 
part, due to a reduction in Bcl-2, Bcl-xl as well as an increase in caspases-3, -8 and - 
9 gene products. Increased CC3 reduced invasiveness of cells as compared to cells 
transfected with empty vector. This reduction could be due to a reduction in matrix 
metalloproteinase-1. 
 
5-Fluorouracil (5-FU)-based adjuvant chemotherapy has been efficacious in reducing 
mortality for lymph node positive colon. We demonstrated that CC3 also contributes 
to resistance to 5-FU. Work on a pair of isogenic cell lines showed that the resistant 
cell line was low in endogenous CC3 and upon 5-FU treatment, CC3-induces 
apoptosis via the mitochondrial pathway and causes cytochrome c release followed 
by activation of the caspases.  
 
In this dissertation, we also define possible mechanism of CC3 silencing by DNA 
hypermethylation. We demonstrated that the promoter of CC3 is hypermethylated, 
leading to a loss of CC3 expression. Upon treatment with 5-Aza-2'deoxycytidine (5-
Aza), a demethylating drug, CC3 expression was up-regulated. A combination drug 
regimen of both 5-Aza and 5-FU, further showed that CC3 was first up-regulated 
ix 
 
followed by increased cell death. This is consistent with our previous finding, where 
exogenous expression of CC3 and 5-Fluorouracil leads to increased cell death. Hence, 
induction of CC3 might be exploited as a therapeutic strategy, along with 5-FU-based 
combinatorial chemotherapy for colorectal cancer. 
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Introduction 
1.1 Colorectal cancer statistics 
Colorectal cancer is the third most common cancer expected to occur and the third 
highest expected number of deaths from cancer, accounting for 9% of all cancer 
deaths,
 
projected for 2008 in both men and women(Jemal, Siegel et al. 2008). In Asia, 
the epidemiology of colorectal cancer has changed and has a rapidly rising trend. 
Data from the CancerBase of the International Agency for Research on Cancer (IARC) 
show that the incidence in many affluent Asian countries is similar to that in the west 
(World Health Statistics Annual. Geneva: WHO Databank. Available at: http://www-
dep.iarc.fr/). In Singapore, colorectal cancer is the second most frequent type of 
cancer for both sexes. It accounts for 17% of all cancers in men and for 14% in 
women(Seow A 2004). From the WHO Mortality Database(Sung, Lau et al. 2005),
 
colorectal-cancer mortality has doubled in both men and women over the past three 
decades in Singapore. The rising trend in incidence and mortality highlights the 
importance of understanding the mechanism and molecular pathogenesis underlying 
colorectal cancer. 
 
1.2 The Anatomy of Normal Colonic Crypts 
In order to understand how tumorigenesis of the colon occurs, we have to appreciate 
the architecture of normal colonic crypt organization. The colon epithelium is a single 
layer of highly specialized cells that act as the initial physiological barrier separating 
the external environment of the lumen from the internal, sterile environment of the 




colon crypt(Booth and Potten 2000). Once they are ―born‖ from the slowly dividing 
stem cells, the epithelial cells undergo three to four cell divisions as they move up the 
crypt-villus axis(Bullen, Forrest et al. 2006). This proliferative zone takes up the 
bottom two-thirds of the colon crypts whereas the differentiated cells constitute the 
top third of the surface epithelium(Radtke and Clevers 2005), as shown in figure 1.1. 
Continuous proliferation of these cells ensures that the single cell barrier of the 
epithelium is renewed. However, this also increases the risk of mutagenic damage and 
cancer development. 
 
Figure 1.1 Normal epithelium of human, showing colonic crypts and surface 
epithelium. Cells prone to death are stained by apoptotic marker Bax (brown nuclei) 
(Immunohistochemical staining is performed by candidate) 
 
 
1.3 Cancer is a disease of deregulated cell proliferation 
 Despite the variability between the various forms of cancer, there are common 
underlying key steps that govern cellular transformation. Weinberg defined six 





de-sensitization to anti-growth signals, (3) infinite replicative potential, (4) resistance 
to apoptosis, (5) enhanced angiogenesis and (6) ability to invade and 
metastasize(Hanahan and Weinberg 2000). Cancer can also be described as a disease 
of dysregulated survival and characterized by evading apoptosis (described more in 
detail in section 1.5). Along the multi-step pathway of tumorigenesis, cancer cells are 
faced with a variety of death inducing situations. Rapidly proliferating cells need to 
survive the harsh conditions of oxygen and nutrient deprivation(Graeber, Osmanian et 
al. 1996). Blocking the apoptotic signaling pathway allows cancer cells to survive 
while attaining capabilities to expand the vasculature. In the process of metastasis, 
cancer cells are faced with cell-death inducing signals. While cancer cells are in the 
circulation, they need to evade the body’s immune surveillance and survive 
mechanical stress. Having an advantage over apoptosis sustains the cancer cell though 
its migration from the primary site into the blood stream and promoting growth at the 
secondary site(Mehlen and Puisieux 2006). 
 
Like other cancers, colorectal cancer may originate from a benign tumor, which can 
transform into a malignant cancer through a step-wise progression known as the 
Adenoma-Carcinoma Sequence. About 2.5% of polyps will transition into cancer 
over a five-year period(Stryker, Wolff et al. 1987). 
 
1.4 Prognostic Indicators in Colorectal Cancer  
The most widely used prognostic indicator for colorectal cancer is tumor staging. The 
original classification developed and subsequently modified was the Duke's 
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classification system. When diagnosed at an early localized disease stage (Dukes A), 
patients undergo curative surgical resection. Dukes B patients, in which there is 
localized spread with no lymph node involvement, are treated surgically with or 
without 5-fluorouracil (5-FU) based adjuvant chemotherapy. In the advanced disease 
setting, in which there is lymph node involvement (Dukes C) or metastasis to other 
organs (Dukes D), the current treatment paradigm is surgical resection followed by 
adjuvant 5-FU-based chemotherapy. 
The Tumor/Node/Metastases TNM staging was developed by the International Union 
Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) and this 
system scores the progression of tumor and its stage of development. The first 
measurement describes the size and extent of invasion primary tumors, in an 
increasing order by size) (T1,T2,T3,T4).  The second measurement describes the 
extent of metastases to regional lymph nodes (N0,N1,N2). The third describes the 
metastases to distant sites like liver and lungs. An alternative way of characterizing 
progression of cancer can be described by Stage I-IV. Stage I and II can be of any 
tumor size (T1-4) and have no evidence of regional or distant metastases. Stage III 
tumors can be of any sizes (T1-4) and evidence of one or more regional lymph node 
metastases. Stage IV tumors can be of any T and N and included distant metastasis. 
 
Tumor grade is an additional prognostic factor in colorectal cancer and
 
its grading 
system is based on the percentage of gland formation. Tumors can be stratified into 
four grades as follows: Grade 1: Well differentiated, Grade 2: Moderately 
differentiated, Grade 3: Poorly differentiated and Grade 4: Undifferentiated. 
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Histological grade has been shown by numerous multivariate analyses to be a stage-
independent prognostic factor in colorectal cancer(Compton, Fenoglio-Preiser et al. 
2000). Specifically, high tumor grade has been shown to be an adverse prognostic 
factor. 
 
While these are well established prognostic factors in colorectal cancer, molecular 
markers may also be useful prognostic and predictive indicators in colorectal cancer 
as they have been shown to be in other cancers. In breast cancer, for example, the 
presence of ERα correlates with increased disease-free survival and an overall better 
prognosis compared to breast cancers that lack ERα, which are characterized by a 
more aggressive phenotype and a poor prognosis.Many of the genetic changes leading 
to the multi-step progression from adenoma to carcinoma have been described, such 
as mutations of the adenomatous polyposis coli (APC) gene, K-Ras(Morris, Curtis et 
al. 1996), SMAD2, SMAD4(Thiagalingam, Lengauer et al. 1996), p53(Nigro, Baker 
et al. 1989) and mismatch repair genes (hMSH2, hMLH1, PMS1, GTBP(Kinzler and 
Vogelstein 1996; Perucho 1996; Chung 2000). The adenoma-carcinoma sequence 
( also known as Chromosomal instability pathway) was first proposed by Fearon and 
Vogelstein(Fearon and Vogelstein 1990). Mutations in the APC gene occur at early 
stages, during the development of polyps, K-ras mutations arise during the 
adenomatous stage, and mutations of p53 and deletions on chromosome 18q occur 
concurrently with the transition to malignancy. p53 protein is a transcription factor 
that negatively regulates cell division and initiates apoptosis. TP53 mutations are 
frequently observed in the late stages of tumor growth(Baker, Preisinger et al. 1990). 
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Chromosome 18q contains genes like Smad2 and Smad4, both of which are 
frequently mutated in the transition of intermediate to late adenoma. These genes 
encode for proteins that function in TGF-β signaling pathway. Hence, when mutated, 
TGF-β pathway no longer propagates growth signals(Xu and Attisano 2000). 
Hypermethylation of various genes have also been implicated in colorectal cancer 
development and progression(Toyota, Ahuja et al. 1999). Examples include several 
tumor suppressor genes, such as INK4A(p16) cell cycle regulator(Herman, Merlo et 
al. 1995), as well as others, such as hMLH1 nucleoside mismatch repair gene, THBS1 
angiogenesis inhibitor(Kane, Loda et al. 1997), and TIMP3 metastasis 
suppressor(Cameron, Bachman et al. 1999). Both genetic and epigenetic changes 
have been recently proposed to be used as candidate biomarkers(Jankowski and Odze 
2009). For example, one highly useful molecular biomarker is identification of 
germline mutations in the APC gene, which can be associated with a 98% risk of 
colorectal cancer by 40 years of age(Gupta, Harpaz et al. 2007).  
 
Accumulating evidence has shown that colorectal cancer is heterogeneous and 
complex. However, with rapid advances in understanding molecular genetics and 
epigenetics of colorectal cancer, these may contribute to its prevention and diagnosis 
and to effective therapeutics in the future. 
 
1.5 Apoptosis 
Necrosis is a form of passive cell death which is characterized morphologically by 
vacuolation of the cytoplasm, breakdown of the plasma membrane and inflammation 
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around dying cell due to the release of cellular contents and pro-inflammatory 
molecules(Proskuryakov, Gabai et al. 2002). In1972, Kerr et al. introduced the 
concept of apoptosis as a form of cell death that was distinct from necrosis(Kerr, 
Wyllie et al. 1972). Most of the morphological changes that he observed are caused 
by a set of cysteine proteases activated specifically in apoptotic cells. These proteases 
belong to a large protein family known as the caspases(Alnemri, Livingston et al. 
1996). All known caspases possess an active-site cysteine, and cleave substrates after 
aspartic acid (Asp-XXXX); a caspase's distinct substrate specificity is determined by 
the four residues amino-terminal to the cleavage site(Thornberry, Rano et al. 1997)
 
. 
Upon cleavage of a series of cellular substrates, these bring about characteristic 
morphological and biochemical changes in the cell including chromatin condensation, 
nuclear fragmentation, membrane blebbing and cell shrinkage. The cell eventually 
breaks down into small membrane-bound fragments (apoptotic bodies) that are 
cleared by phagocytosis without causing an inflammatory response(Hengartner 2000). 
Activation of caspases works by proteolytic cleavage of caspase zymogen and 
subsequently, in a cascade manner where signals are amplified. Based on their 
function, the caspases are classified into three subtypes. Caspase-1, -4, -5, -11, -12, -
13 and -14 are inflammatory caspases and are not involved in apoptosis. Apoptotic 
initiator caspases, like caspase-2, -8, -9 and -10 are activated by interactions with 
upstream adaptor molecules and are recruited to large protein
 
complexes (eg "death-
inducing signaling complex; DISC). Lastly,  these initiator caspases cleave apoptotic 
effector caspases (caspase-3, -6 and -7) and perform the downstream execution steps 




In fact, many of the effects of the chemical and physical agents that are commonly 
used in the treatment of human malignancies are mediated by induction of 
apoptosis(Eastman 1990; Dive and Hickman 1991; Schmitt and Lowe 1999) and thus 
rely at least in part on the same biochemical mechanisms involved in physiological 





1.5.1 Intrinsic and Extrinsic apoptotic pathways 
Apoptosis can be induced by various stimuli, including growth
 
factor withdrawal, 
irradiation, cytotoxic drugs and death receptor
 
ligands. There are two major signaling 
pathways in mammalian
 
cells leading to apoptosis, the extrinsic pathway (triggered
 
by 







































Figure 1.2 Intrinsic and extrinsic pathway of apoptosis (Adapted from H 
Schulze-Bergkamen et al)(Schulze-Bergkamen, Weinmann et al. 2009).  
Apoptosis can be triggered by two pathways. The extrinsic pathway is initiated by binding of 
ligands to death receptors on the cell surface. The intrinsic pathway is triggered at the 
mitochondria by various stimuli—for example, chemotherapy. Initiator caspases (caspase-8, -
9 and -10) then activate effector caspases (caspase-3, -6 and -7). Effector caspase activation 
results in the cleavage of death substrates. There is a cross-talk between the two pathways as 
caspase-8 can activate Bid, which in turn activates mitochondria.  
Apaf-1, apoptotic protease-activating factor-1; cyt c, cytochrome c; DISC, death-inducing 
signaling complex; IAPs, inhibition of apoptosis proteins; Smac/DIABLO, second 
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Both the intrinsic and extrinsic are the two main interlinked pathways that can induce 
apoptosis by activation of caspases (Figure 1.2). The extrinsic pathway is stimulated 
by binding of death receptor
 
ligands to specific death receptors on the cell surface. 
The
 
growing family of death receptors belongs to the tumor necrosis
 
factor (TNF) 
receptor superfamily(Peter, Scaffidi et al. 1999). Death receptors have an
 
intracellular 
death domain (DD) which is essential for the transduction
 
of the apoptotic 
signal(Tartaglia, Ayres et al. 1993). Some of the death receptor
 
family include, 
TNFR1, TNFR2, CD95 (APO-1,
 
Fas), TRAILR1 (TNF-related apoptosis-inducing 
ligand receptor
 
1) (APO-2, DR4) and TRAILR2 (DR5, KILLER, TRICK 2). The 
biological
 
activity of TNF depends upon ligation of TNFR1 and TNF. The most 
important step of death receptor signaling is the formation
 
of multimeric proteins 
triggered by receptor cross-linking
 
with either their agonist(Trauth, Klas et al. 1989).
 
This structure formed is called DISC(Kischkel, Hellbardt et al. 1995). The death 
signal is then propagated by caspase-8
 
and -10 followed by activation of the effector 
caspases-3,
 
-6 and -7.  
 
Both caspase-8 and -10 can also promote activation
 
of the intrinsic pathway, by
 
the 
cleavage of the Bid leading to direct activation
 
of the pro-apoptotic Bcl-2 family 
members BAX and BAK(Ashkenazi 2002). Alternatively, the intrinsic pathway can 
be stimulated by radiation or chemotherapeutic drugs, growth factor deprivation and 
oxidative stress. Bcl-2 family of proteins has an
 
important impact on mitochondrial 
integrity. These proteins
 





die or survive. The family includes at least 20
 
members of pro-
apoptotic and anti-apoptotic proteins and
 
share homology in the Bcl-2 homology 
regions (BH1–BH3). Anti-apoptotic Bcl-2 family members possess all four BH 
homology
 
regions (eg, BCL-2, BCL-XL and MCL-1). Proapoptotic members can
 
either lack the BH4 domain (eg, BAX and BAK) or lack BH1, 2
 
and 4 domains 
("BH3-only proteins", eg, BAD and BIM) (Fig.1.3). The anti-apoptotic
 
Bcl-2 family 
members interact with BAX and BAK to inhibit the
 
activation of mitochondria(Huang 











 Group 1                   Bcl-2 
       
  
   Group 2                   Bax 
           Group 3             Bid 
    
Figure 1.3 Classification of Bcl-2 family proteins 
Members of group1, such as Bcl-2 and Bcl-xl, are characterized by four short, 
conserved Bcl-2 homology (BH) domains (BH1–BH4). They also possess a C-
terminal hydrophobic tail (TM), which localizes the proteins to the outer surface of 
mitochondria, with the bulk of the protein facing the cytosol. Group 1 members 
possess anti-apoptotic activity and protect cells from death. In contrast, group 2 
consists of Bcl-2 family members with pro-apoptotic activity. Members of this group 
include Bax and Bak, have a similar overall structure to group I proteins, except the 
most N-terminal, BH4 domain. Group 3 consists of a large and diverse collection of 
proteins whose only common feature is the presence of the BH3 domain. Anti-
apoptotic proteins (Bcl-2 and Bcl-xl) sequester the pro-apoptotic BH-3 domain only 
proteins in stable mitochondrial complexes, and thus prevent activation and 
translocation of Bax or Bak to mitochondria. 
 
Initiation of the intrinsic pathway results in mitochondrial membrane 
permeabilization (MMP) and release of mitochondrial proteins, including 
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cytochrome-c, HtRA2/Omi and second mitochondria-derived activator of caspase/ 
direct inhibitor of apoptosis protein binding protein with low pI (Smac/DIABLO). 
 
Although the exact mechanism how cytochrome c manages to cross the mitochondrial 
outer membrane is not yet known, several competing hypotheses have suggested that 
the Bcl-2 family is intimately involved in the regulation of this process. 
 
Based on the structural similarity of Bcl-xl to the pore-forming subunit of diphtheria 
toxin(Reed 1997), it was suggested that following a conformational change, Bcl-2 
proteins might act by inserting  into the outer mitochondrial membrane, where they 
could form channels. Another possibility is that Bcl-2 family members interact with 
other proteins such as voltage-dependent anion channel (VDAC) and regulate its 
channel activity(Shimizu, Narita et al. 1999) 
 
Once cytochrome c is released into the cytosol,
 
the "apoptosome" is assembled, a 
multiprotein complex in which
 
apoptotic protease-activating factor-1 (Apaf-1) serves 
as an
 
oligomerization platform for assembly and autoproteolytic activation
 
of  
caspase-9. Caspase-9 mediates activation of the effector
 
caspases-3, -6 and -7, and 
also produces a positive feedback loop
 
in the extrinsic pathway through further 







inactivate the IAP (inhibitors of apoptosis proteins) protein
 
family, which consists of XIAP, IAP1/2 and survivin. XIAP is
 
a direct caspase 
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inhibitor(Du, Fang et al. 2000). Other IAPs including survivin, which is the one most 
differentially expressed between malignant
 
and healthy tissue. 
 
The tumor suppressor gene p53 not only mediates G1growth arrest by inducing the 
cyclin-dependent kinase inhibitor p21/waf1/cip1(Salles-Passador, Fotedar et al. 1999),  
it also regulates the intrinsic pathway in apoptosis by transactivating pro-apoptotic 
Bcl-2 family members and repressing anti-apoptotic Bcl-2 proteins and IAPs 
including survivin in response to DNA damage(Hoffman, Biade et al. 2002) 
 
1.5.2 Measurement of Apoptosis and in vitro Chemo-sensitivity and Resistance 
Assays 
The time from initiation of apoptosis to completion can be as short as 2–3 hr(Bursch, 
Kleine et al. 1990; Bursch, Paffe et al. 1990). Various in vitro apoptotic assays that 
can detect both early and late cellular changes have been developed. Mitochondrial 
assays, cytochrome-c release assay, Phi-PhiLux (fluorescent light) assay and caspase-
3 activity assays help in detecting early apoptotic changes whilst trans-electron 
microscopy, resin embedded tissues stained with toluidine blue or methylene blue, 
Terminal dUTP Nick End-labeling (TUNEL) reaction, Annexin-V assay, and assays 
using vital dyes such as Nile blue sulfate, Neutral red and LysoTracker Red aid in 
detecting late changes(Watanabe, Hitomi et al. 2002) 
 
1.6 Chemotherapeutic treatments 
1.6.1 Therapeutic targeting of cell proliferation and apoptosis 
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Because deregulated proliferation and inhibition of apoptosis are obvious 
mechanisms of all tumor development, they present two obvious targets for 
therapeutic intervention in all cancers.  
 
5-Fluorouracil (5-FU)-based adjuvant chemotherapy has been efficacious and in 
reducing mortality for lymph node positive colon cancer and has been the standard of 
care ever since it was introduced in 1957(Hoff, Cassidy et al. 2001; Chau and 
Cunningham 2002; Tebbutt, Cattell et al. 2002; Xiong and Ajani 2004). Most notably, 
5-FU is routinely employed in the management of colorectal cancer via one of two 
FDA-approved first line combinatorial chemotherapy regimes, abbreviated FOLFOX 
and FOLFIRI, which involve intravenous administration of 5-FU. The 5-year survival 
of Dukes B patients undergoing surgical resection alone is approximately 75%, 
indicating that about 25% of Dukes B patients may potentially benefit from adjuvant 
chemotherapy. In the Duke C and Duke D patients, the current treatment paradigm is 
surgical resection followed by adjuvant 5FU-based chemotherapy. 
 
5-FU is a uracil analog and is rapidly incorporated into the cells using the same 
facilitated transport system as uracil(Wohlhueter, McIvor et al. 1980). Subsequently, 
5-FU is converted into active metabolites which disrupt the action of thymidylate 
synthetase (TS) and RNA synthesis. The metabolism of 5-FU is shown in 
figure1.4(Longley, Harkin et al. 2003). Nonetheless, response rates for 5-FU-based 
chemotherapy as a first line-treatment for advanced colorectal cancer are only 10-
15%(Johnston and Kaye 2001). More recently, combination therapy of 5-FU with 
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Irniotecan and Oxaliplatin has been shown to improve response rates to 40-50%.  
Despite these improvements, new therapeutic strategies are required and 
understanding the mechanistic actions of 5-FU increases our ability to predict 5-FU 
response. 
 
1.6.2 Determinants of responses to 5-FU 
TS and 5-FU-metabolizing enzymes such as dihydropyrimidine dehydrogenase (DPD) 
and thymidine phosphorylase (TP) have been analyzed to elucidate 5-FU 
resistance(Longley, Harkin et al. 2003). The anti-cancer activity of 5-FU works best 
when its degradation is reduced or activation enhanced. Patients with low TS 
expression(Johnston, Lenz et al. 1995; Edler, Blomgren et al. 1997) and low DPD 
mRNA levels(Salonga, Danenberg et al. 2000) show improved response to 5-FU 
based therapy. The role of TP in modulating 5-FU responsiveness is less obvious as 
clinical data showed that high TP levels showed poorer response to 5-FU(Metzger, 
Danenberg et al. 1998), whereas re-clinical data showed an opposite trend.  However, 
the resistance to 5-FU has not been sufficiently explained by the metabolic pathway 
of 5-FU alone, because multiple factors can participate in chemoresistance. Recently, 
complementary DNA (cDNA) microarray technology has been used to identify novel 
genes regulating 5-FU resistance, and the potential biomarkers of 5-FU resistance 
other than pyrimidine metabolism-related enzymes have been proposed(Zembutsu, 
Ohnishi et al. 2002; Maxwell, Longley et al. 2003).  Other pathways which 5-FU can 
act includes incorporation into DNA, resulting in inhibition of cell cycle progression 
into S phase(Copur, Aiba et al. 1995; Sobrero, Kerr et al. 2000; Tebbutt, Cattell et al. 
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2002) as well as DNA damage and finally by inducing apoptosis(Lowe, Ruley et al. 
1993; Liu, Page et al. 1999; Shi, Liu et al. 2002; Violette, Poulain et al. 2002). 
Central to this response are proteins that modulate apoptosis, including bcl-2 and bax 
gene products(Bargou, Daniel et al. 1995). 
5-FU is generally known to cause genomic incorporation and induce G1-S-phase 
arrest thereby blocking the proliferation of tumor cells. Recent studies have suggested 
DNA damage responses play a key role in dictating cellular responsiveness to 5-FU 
exposure. Endogenous DNA damage response genes are responsible for any external 
changes incorporated to DNA, including that induced by 5-FU. Reports imply that 
enzymes involved in mismatch repair (MMR) and base excision repair (BER) are 
important. A number of studies have reported that cells deficient in MMR 
components, particularly MLH1 MSH2, are resistant to 5-FU(Carethers, Chauhan et 
al. 1999; Meyers, Wagner et al. 2001; Meyers, Wagner et al. 2005). For BER, 
SMUG1 glycosylase functions predominantly in cellular 5-FU repair although there 
has not been any clinical study to show its association with 5-FU treatment.  
 
Increased resistance to chemotherapeutic agents was shown to have an association 
with decreased capacity to undergo apoptosis(Sakakura, Sweeney et al. 1996) and the 
Bcl-2 family was central to this response but in a cell type-dependent manner. In 
clinical studies, Bcl-2 protein expression or gene activation have been associated with 
poor response to therapy and/or shorter disease-free survival in some groups of 
patients with lymphomas(Yunis, Mayer et al. 1989), leukaemias(Campos, Rouault et 
al. 1993), prostate cancer(McDonnell, Troncoso et al. 1992), breast cancer(Bonetti, 
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Zaninelli et al. 1998; Daidone, Veneroni et al. 1999) and colorectal cancer(Pezo, 
Gandhi et al. 2008) . On the other hand, bcl-2 positivity in head and neck tumors was 
either, highly associated(Gasparini, Bevilacqua et al. 1995; Homma, Furuta et al. 
1999) or independent(Costa, Licitra et al. 1998) of the response to treatment. In 
metastatic breast cancer, poor response to chemotherapy and short survival was 
observed in a subgroup of patients whose tumors showed reduced Bax 
immunostaining(Krajewski, Blomqvist et al. 1995) . Similarly, it was shown that high 
Bax expression in ovarian cancer was associated with a significant increase in the 
percentage of complete remissions after first-line chemotherapy and with an 
improvement in survival(Tai, Lee et al. 1998). It was also shown that there was a 
positive predictive role of high Bax immunostaining in the outcome of adjuvant 
chemotherapy in stage III colon cancer and is also independently linked to an 
improved rate of disease recurrence(Nehls, Okech et al. 2007). 
 
In 2002, Peterson et al. identified four pathologically defined markers to potentially 
be used in stratifying Dukes B colorectal cancer patients for relapse following 
surgical resection, and therefore would benefit from adjuvant chemotherapy(Petersen, 
Baxter et al. 2002). These pathological markers were defined as peritoneal spread, 
venous spread, surgical margin spread, and tumor perforation. Each marker was 
scored to generate a prognostic index (PI) with patients classified as low or high risk 
for recurrence. The effectiveness of this method of stratification of Dukes B patients 
was recently shown to be limited due to often inadequate pathological reporting 
(Morris, Maughan et al. 2007), indicating an ever pressing need for the identification 
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of more useful biochemical markers. Research efforts have increased our 
understanding of how 5-FU mediates its effects, and specific targets to inhibit their 
growth have been identified. However, in advanced colorectal cancer the search for 
indicators of response or biomarkers still represent a valuable approach to potentially 
improve the therapeutic decision. 
 
  
Figure 1.4 Metabolism of 5-FU 
Dihydropyrimidine dehydrogenase (DPD)-mediated conversion of 5-FU to 
dihydrofluorouracil (DHFU) is the rate-limiting step of 5-FU catabolism in normal 
and tumor cells. Up to 80% of administered 5-FU is broken down by DPD in the liver. 
Catabolism of 5-FU works to inhibit TS. Hence, if cancers over-express TS, they 
become more resistant to 5-FU. 
1.7 Epigenetics 
In addition to direct genetic mutations, modifications to DNA can also affect gene 
expression. The process of stable, inheritable gene modification without direct change 
to DNA sequence is termed epigenetics(Herman, Merlo et al. 1995). Methylation of 
cytosines in the 5’-position of the pyrimidine ring is the most important epigenetic 
alteration. In animals, methylcytosine is mainly found in cytosine-guanine (CpG) 
RNA Damage DNA Damage 
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dinuleotides(Bird 1986). The presence of 5-methylcytosine in the promoter of 
specific genes prevents binding of transcription factors. In addition, the presence of 5-
methyl group attracts methyl-DNA-binding proteins and histone deacetylases, around 
the transcription start site. Both mechanisms lead to gene silencing(Bird 1986). Gene 
silencing by methylation has a similar effect to inactivating mutations and has only 
been recently recognized to be of critical clinical importance in 
tumorigenesis(Herman and Baylin 2003).   
 
1.7.1 DNA methylation 
The pattern of DNA methylation is maintained after DNA replication in cell division 
by a family of DNA methyltransferases (DNMTs). DNMTs act by the addition of a 
methyl group to the carbon-5 position of
 
cytosine at CpG dinucleotides (Fig 1.5). 
DNA methylation of genes occurs mainly in the promoter region that contains CpG 
islands. CpG islands are defined as a 0.5-4kb stretch of DNA that contains CpGs 
dinucleotides at higher frequency than the rest of the genome. In normal cells, 
dinucleotides in the CpG islands, especially those associated with gene promoters are 
usually unmethylated.  However, there are exceptions to methylation of CpG islands 
in physiological events; for example, X-chromosome inactivation in females and 
maintenance of heterochromatic regions of the genomes is due to methylation in gene 
promoters. However, in cancers, aberrant hypermethylation of these promoter regions 
is associated with
 
transcriptional silencing of many genes (Fig 1.6). Several
 
tumor 
suppressor and other cancer genes have been found to be
 
hypermethylated in cancers 
but to be unmethylated in normal
 





adenomatous polyposis coli (APC), and death-associated protein
 
kinase (DAP-kinase) genes(Esteller, Corn et al. 2001; Holst, Nuovo et al. 2003). 
 
1.7.2 Reactivating silenced genes 
One critical difference between classical mutations and epigenetic silencing is that 
epigenetic changes are reversible. The potential reversibility of epigenetic states 
offers exciting
 
opportunities for novel cancer drugs that can reactivate epigenetically
 
silenced tumor-suppressor genes(Kondo, Shen et al. 2003). The demethylating agent, 
5-azacytidine and its deoxy derivative 5-aza-2’-deoxycytidine (5-aza-dC) are 
powerful inhibitors of DNA methylation, as they are incorporated into nucleic acids 
of dividing cells (replacing cytosine).  In 5-aza-dC, since carbon-5 is substituted by 
nitrogen (Fig 1.5), DNMT remains covalently bound to 5-aza-dC and its DNA 
methyltransferase function is blocked.  As a consequence, methylation marks become 






































Figure 1.5 Methylation of Cytosine in the Mammalian Genome and Inhibition of 
methylation with 5-Azacytidine.  
DNA methyltransferases (DNMTs) catalyzes the methylation of the 5 position of the 
cytosine ring, using S-adenosyl-methionine as the donor molecule for the methyl 
group (CH3). This reaction can be blocked by the drug, 5-azacytidine. When this 
compound is integrated into DNA, replacing the natural base cytidine, it acts as a 
direct and irreversible inhibitor of the DNMTs, since it contains a nitrogen in place of 

















Figure 1.6 Methylation in normal and cancer cells.  
In normal cells, most CpG sites outside of CpG islands are methylated (black circles), 
whereas most CpG-island sites in gene promoters are unmethylated (white circles). 
This methylated state in the bulk of the genome may help suppress unwanted 
transcription, whereas the unmethylated state of the CpG islands in gene promoters 
permits active gene transcription (arrow in upper panel). In cancer cells, the DNA-
methylation and chromatin patterns are shifted. Many CpG sites in the bulk of the 
genome and in coding regions of genes, which should be methylated, become 
unmethylated, and a growing list of genes have been identified as having abnormally 
increased methylation of promoters containing CpG islands. DNMT: DNA 
methyltransferase. (Herman and Baylin 2003). 
 
1.7.3 Methods to study methylation 
The wide distribution of hypermethylated genes across human genome and searching 
candidate tumor suppressor genes has spurred efforts to screen for such genes. There 
are growing numbers of techniques developed for this purpose. 3 main techniques are 
commonly used depending on the information required. High-Performance Liquid 
Chromatography (HPLC)(Gama-Sosa, Midgett et al. 1983)-or High-Performance 
capillary electrophoresis (HPCE)(Fraga, Rodriguez et al. 2000) -based methods are 









It is useful for the rapid quantification of the degree of global DNA methylation and 
its exploitation for the analysis of poorly purified and/or concentrated DNA samples, 
such as tumor biopsies. Briefly, DNA for studies first undergoes enzymatic 
hydrolysis. Resulting deoxyribonucleosides are subsequently separated by HPLC or 
HPCE and methylcytosine levels are quantified by comparing relative absorbance 
cytosine and methylcytosine at 254nm with external standards of known bases. A 
second method, in situ hybridization with methylcytosine-specific antibodies, can 
also be employed to study global hypermethylation (Miller, Schnedl et al. 1974). 
Cytosine methylation can be detected in metaphase chromosomes and chromatin by 
using specific 5-methylcytosine monoclonal antibodies. Quantification of in situ 
DNA methylation can be achieved by immunofluorescence analyses in image 
analyzers(Veilleux, Bernardino et al. 1995). However, the most commonly used and 
described as a ―gold-standard‖ method of studying DNA methylation patterns of 
specific regions is by bisulfite modification of DNA(Clark, Harrison et al. 1994). 
Bisulfite discriminates between unmethylated and methylated cytosines. The basis of 
this method is that, bisulfite treatment of genomic DNA effectively deaminates 
unmethylated cytosine residues to uracil, while 5-methylcytosines are resistant to this 
treatment and remain unchanged. After denaturation, bisulfite-treated DNA can be 
used as template in a standard PCR, in which uracils (formerly unmethylated 
cytosines) will be amplified as thymine and only 5-methylcytosines will be amplified 
as cytosine, to generate a PCR product. Methylcytosine can then be identified by 
direct sequencing differentiating between cytosines and thymines. Alternatively, PCR 
products can be cloned into plasmids and transformed into bacteria before sequencing 
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individual clones. Cloning and sequencing is the only available method that can give 
single-nucleotide resolution for methylation across the DNA molecule. In contrast, 
direct sequencing of PCR products give average values of methylation status in the 
population of DNA molecules. 
 
Despite the accuracy of sequence analysis to distinguish between cytosine and 5-
methylcytosine, sequencing after bisulfite treatment approach is still laborious and 
may not be the most rational approach to detect aberrant DNA methylation. Many 
other PCR-based methods have been developed to analyze bisulfite-treated DNA, 
including methylation-specific PCR (MSP)(Herman, Graff et al. 1996), combined 
bisulfite restriction analysis (COBRA)(Xiong and Laird 1997), methylation sensitive 
single nucleotide primer extension (Ms-SnuPE)(Gonzalgo and Jones 1997) , 
MethyLight(Eads, Danenberg et al. 2000), HeavyMethyl(Cottrell, Distler et al. 2004) 
and methylation specific melting curve analysis (MS-MCA)(Worm, Aggerholm et al. 
2001). MSP has been a popular technique used due to its simplicity. Primers are 
designed to distinguish methylated from unmethylated DNA in bisulfite-modified 
DNA, taking advantage of the sequence differences resulting from bisulfite 
modification. Unmodified DNA or DNA incompletely reacted with bisulfite can also 
be distinguished, since marked sequence differences exist between these 





1.7.4 Early detection of cancer  
The detection of methylated DNA sequences has become increasingly simple and 
sensitive and as a result, DNA promoter hypermethylation is now a potentially useful 
biomarker. The use of this approach has allowed detection of methylated DNA in 
serum(Lee, Leung et al. 2002; Zou, Yu et al. 2002), sputum(Palmisano, Divine et al. 
2000), urine(Cairns, Esteller et al. 2001), lymph nodes(Sanchez-Cespedes, Esteller et 
al. 1999), stools(Huang, Li et al. 2007) in different cancers. 
Methylation of tumor suppressors plays an important role in development of many 
cancer types. Identification of genes that are inactivated by hypermethylation of gene 
promoters will lead to insights into novel disease mechanisms and also development 
of new diagnostic molecular markers and potential therapies. 
 
1.8 CC3 
The CC3 gene, also known as TIP30 and Htatip2, was first identified as a novel 
tumor suppressor gene of variant small cell lung carcinoma (v-SCLC) as its over-
expression was found to suppress the metastatic potential of v-SCLC 
cells(Shtivelman 1997).  CC3 gene is located on human chromosome 11p15.1. CC3 
encodes a relatively small protein of 30kDa that is highly-conserved in Homo sapiens 
and Mus musculus with more than 80% homology. A recent crystal structure analysis 
proposed that CC3 could be a metabolic sensor linked to its apoptotic property. The 
crystal structure of CC3 indicates that it belongs to the short chain dehydrogenase 
(SDR) superfamily, where NADPH serves as the most physiological ligand(El Omari, 




1.8.1 Functional Studies in CC3 
Consistent with its proposed function as a tumor suppressor gene, the CC3 gene is 
expressed at a low level in a number of highly aggressive tumor cell lines derived 
from colon cancer, SCLC and human hepatocellular carcinoma (HCC) (Hewitt, 
Brown et al. 2000; Whitman, Wang et al. 2000; Shi, Zhang et al. 2005; Zhao, Ni et al. 
2007). Strong evidence which suggests that CC3 is a tumor suppressor gene has come 
from knock-out studies in mice:  Deletion of one or both alleles of the CC3 gene 
resulted in spontaneous development of a variety of tumors, including HCCs, 
transitional cell carcinoma of the bladder, leiomyoma of the uterus and a lipoid cell 
tumor of the ovary and an haemangiosarcoma, as well as ductal hyperplasia and 
tumors in the mammary glands (Ito, Jiang et al. 2003).  
 
Two different mechanisms by which CC3 exerts this tumor suppressing effect have 
been identified. The first mechanism is an apoptosis-inducing effect, where ectopic 
expression of CC3 causes a caspase-dependent cell death via the mitochondrial 
pathway(Shi, Yan et al. 2008). The pathway of apoptosis is either p53 dependent or is 
due to a direct modulation of Bcl-2 family. In addition, exogenous expression of CC3 
sensitized HCC cell lines to various chemotherapeutic drugs and death inducing 
ligands (Shtivelman 1997; Zhao, Zhang et al. 2006). CC3 cDNA sequences in 
National Center for Biotechnology Information Database (NCBI) were analyzed and 
24% of various types of cancer harbored at least a single base-pair substitution and 
none of the normal cells had mutations in the same region. In eight hepatocellular 
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carcinomas of low CC3 expression, 3 of 8 samples showed single base pair mutations. 
Substitution in G134V affected stability of CC3 half life, hence possibly reducing its 
expression. R106H substitution abrogates nuclear localization of CC3(Ito, Jiang et al. 
2003). 
 
The second proposed mechanism for CC3’s tumor suppressive action is an indirect 
angiogenesis-inhibiting effect, where over expression of  CC3 upregulates the 
expression of certain angiogenic inhibitors, like Angiopoietin 2 and downregulates 
angiogenic stimulators, like Angiopoietin 1, by a number of tumor cell 
lines(NicAmhlaoibh and Shtivelman 2001).   
 
Evidence that CC3 may function as a metastasis suppressor has recently come to light. 
Tong et al showed that subcutaneous injection of CC3 over-expressing lung cell lines 
resulted in a reduced tumor size. Furthermore, cancer metastasis model by tail vein 
injections showed that mice injected with CC3 over-expressing cells had lower 
occurrence of lung metastases(Tong, Li et al. 2009). This metastasis suppression was 
due to an inhibition in osteopontin (OPN) transcription. OPN is an ECM protein 
which binds to families of receptors and enhances tumor 
progression. These were in line with in vitro assays where ectopic expression of CC3 
resulted in cell invasion through extracellular matrix (ECM) and adherence to 
fibronectin.  The conditioned media from CC3-expressing tumor cells also greatly 
inhibited the proliferation and migration of endothelial cells in vitro(NicAmhlaoibh 




In a separate study, by Jiang and co-workers, CC3 was identified as a cellular protein 
capable of binding to HIV-Tat protein and contributing to the transcriptional effects 
of the latter(Xiao, Tao et al. 1998). In addition, CC3 was found to interact with 
estrogen receptor (ERα )-interacting co-factor and negatively regulate ERα-mediated 
c-myc expression(Jiang, Ito et al. 2004).  CC3 was found to inhibit nuclear import of 
transportin and ultimately cause cell death(King and Shtivelman 2004). 
 
Other than functions in tumorigenesis, CC3 was found to be induced by TGF-β1 in 
cells cultured by in three dimensional collagen gel(Lindfors, Halttunen et al. 2001). 
Cells cultured in this in vitro system organize into three-dimensional luminal 
formations and mimics intestinal crypts and villus. Upon stimulation of TGF-β1, up-
regulation of CC3 was accompanied with cell differentiation. 
 
1.8.2 Studies of CC3 expression in tissues 
The controversy arose when CC3 expression was investigated in breast and prostate 
cancers tissues. While a lower CC3 expression was expected in more aggressive 
cancer, the opposite trend was found. In breast cancers, CC3 expression was 
conflicting. Zhang(Zhang, Wong et al. 2005) reported that CC3 was not correlated 
with tumor stage, grade  and lymph node status but was associated with Her2/neu 
status, an established adverse prognostic factor in breast cancer. They also found 
higher expression of CC3 in tumors compared to normal tissues.  Similarly, 
Zhao(Zhao, Ni et al. 2007) found no association with tumor stage, or grade and no 
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correlation with p53 status.  However, they found lower CC3 expression in lymph 
node.  Also, tumors with lower CC3 had increased vascular invasion, in line with its 
proposed tumor suppressive function(Zhao, Ni et al. 2007). There were no mutations 
in CC3 found in either breast cancer studies, unlike in the studies on HCC, which 
suggests mutations may be somatic. Another unexpected result was that CC3 
expression was localized to the cytoplasm in both publications. It was previously 
hypothesized that CC3 may be a transcriptional cofactor(Xiao, Tao et al. 1998; Jiang, 
Ito et al. 2004) hence this finding did not appear consistent with its function. In a 
separate prostate cancer study, the authors found evidence of an oncogenic role for 
CC3, since its expression was higher in metastatic and recurrent prostate cancer. The 
localization of CC3 in normal tissues was exclusive to the cytoplasm while that of the 
metastatic tissue was nuclear. In addition, increased CC3 expression was associated 
with invasion and metastasis(Zhang, Zhang et al. 2008).  These findings suggest that 
CC3 may have bifunctional roles and its mechanism of action may be highly cell-type 
specific. Hence, it is necessary to investigate the role of CC3 in other cancer types in 
order to understand its function in human carcinogenesis.  
 
The opposing trends in the four major cancer types are intriguing. One possibility is 
that CC3 may play a different role in different cancers, perhaps due to the different 
nature of cancer. Another possibility is that the antibodies used in these different 
studies had different specificities.  They were all polyclonal antibodies coming from 
various sources.  The unexpected subcellular localization of CC3 immunostaining 
also gives some reason for concern:  Only prostate samples showed nuclear staining, 
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correlating to its proposed function as a transcriptional cofactor. Hence, production of 
highly specific and reliable monoclonal antibodies may provide a clearer explanation 
to the observed controversy and eliminate any non-specific binding due to the nature 
of the antibody. In addition, the ethnicity of patients were different in the studies and 
a new study which includes tissue samples from both Asian and Western countries 
might provide better insight to the expression of CC3 in different cancer sub-types. 
 
1.8.3 Methylation of CC3 
Recently, a genome-wide investigation was performed to identify genes that display 
evidence of methylation-dependent regulation. Expression microarray analysis of 
medulloblastoma cell lines following treatment with a DNA methyltransferase 
inhibitor show re-expression of multiple transcripts, including CC3(Anderton, 
Lindsey et al. 2008). In addition, CC3 promoter was unmethylated in normal 
cerebellum tissues but highly methylated in medulloblastoma cancer cell lines as 
shown by bisulfite sequencing. This was followed next with a separate study in 
hepatocellular carcinoma, where methylation of CC3 was found in 47% of the tumors 
while it was not methylated in any of the matched normal tissues(Lu, Ma et al. 2008). 
In addition, CC3 promoter methylation was associated with poorer prognosis. Both 
the findings provide good justification for further studies of promoter 





1.9 Hypothesis, objectives and significance: 
Based on studies done by other groups(Shtivelman 1997; Ito, Jiang et al. 2003), as 
well previous data from our laboratory(Zhang, Wong et al. 2005), we hypothesize 
that CC3 act as a tumor suppressor in colorectal cancer. 
The overall objective of this dissertation is to determine the role of CC3 in colorectal 
cancer. The specific aims used to address this objective encompass a combination of 
histology and molecular techniques.  
1) To our knowledge, there is no information available on the expression of CC3 
in colorectal clinical samples. We therefore propose to determine CC3 
expression levels in colorectal cancer by a validated novel monoclonal 
antibody .The first specific aim was to accurately access CC3 expression in 
colorectal tissues. We developed a monoclonal antibody for immunostaining 
of colorectal cancer tissues from different stages. A small number of matched 
lymph node and liver metastases were also assessed to determine if CC3 was 
associated with metastasis. Since we have established and validated the 
accuracy of CC3 monoclonal antibody, a panel of precancerous colorectal 
tissues comprising of inflammation hyperplasia and polyps, as well as normal 
and cancer tissues of various types were included in the study  to expand our 
initial findings on in vivo expression of CC3. The mRNA levels of CC3 were 
also accurately assessed by laser capture microdissection of colorectal tumor 




2) The second specific aim was to determine the significance and mechanisms of 
CC3 overexpression in colorectal cancer cell lines. Functional assays were 
performed to observe if cell lines stably transfected with CC3 had effects on 
proliferation, clonogenicity, apoptosis, and invasion. Based on the results of 
functional assays, further analysis of caspase activation and changes in expression 
of various regulators of apoptosis in the Bcl-2 family were performed. In addition, 
most reports in the literature have focused on the direct apoptotic effects of CC3 
in hepatocelluar carcinoma. There are no reports addressing how CC3 is being 
regulated upon chemotherapeutic drug treatments. The apoptotic role of CC3 in 5-
Fluorouracil treatment was also investigated in this dissertation. 
 
3) The third specific aim was to delineate the regulation of CC3. Since the upstream 
region of CC3 contains a large CpG island, this suggests that CC3 gene 
expression may be silenced in colorectal cancer by promoter hypermethylation. 
 
Data from this dissertation will lay the groundwork for understanding how CC3 may 
play a role in colorectal tumorigenesis and how it sensitizes cancer cells to 
chemotherapeutic drugs. Hence, it may aid in the development of strategies to lower 




MATERIALS AND METHODS 
2.1 CC3 monoclonal antibody production 
As there are no monoclonal antibodies against CC3 available to date, we employed a 
commercial company, Biogenes (Berlin, Germany) to help produce one.  
 
2.1.1Antigen selection 
Four peptide sequences were chosen (underlined) based on the 3-dimensional 
structure of CC3 by Biogenes (Berlin, Germany).         
 
         1 MAETEALSKL REDFRMQNKS VFILGASGET GRVLLKEILE QGLFSKVTLI GRRKLTFDEE 
       61 AYKNVNQEVV DFEKLDDYAS AFQGHDVGFC CLGTTRGKAG AEGFVRVDRD YVLKSAELAK 
      121 AGGCKHFNLL SSKGADKSSN FLYLQVKGEV EAKVEELKFD RYSVFRPGVL LCDRQESRPG 
      181 EWLVRKLFGS LPDSWARGHS VPVVTVVRAM LNNVVRPRDK QMELLENKAI HDLGKAHGSL 
      241 KP 
 
A BLAST analysis showed that all the four sequences were highly specific for the 
CC3 amino acid sequence. A standard mouse hybridoma production method was used.
 
Briefly, peptides were first conjugated to carrier proteins before immunization in 
mice. Bleeds from mice were first tested to determine if the antibody was specific for 
CC3 by Western Blot. Sera from mice inoculated with NLLSSKGADKSSN and 
AMLNNVVRPRDQM peptides failed to detect CC3 in various cell lines (known to 
express high levels of CC3 mRNA) even when neat concentration of bleed was used.  
Sera from mice inoculated with TEALSKLREDFRMQ and GRRKLTFDEEAYKN 
detected CC3.  Therefore, we proceeded with producing hybridoma cell by fusing 
immune spleen cell populations with mouse SP2/0-Ag14 myeloma cells. Selection of 
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stable clones was done in conjunction with CC3 protein blocking. ELISA was used 
for this screening. Briefly, 96 well flat-bottom polystyrene microtiter plates (Greiner) 
were coated with BSA peptide conjugate or CC3 protein. After incubation overnight 
in a moist chamber at 4°C, a series of washing and blocking steps were performed. 
Cell culture supernatants, containing the antibodies, were then added to the wells and 
signals were amplified by goat anti-mouse IgG conjugated to alkaline. After the 
addition of substrate buffer, signals were detected by microplate reader at 405nm  
 
In wells pre-coated with CC3 protein, the signals were abolished. Supernatants from 
clones that have TEALSKLREDFRMQ peptide had higher signals compared to 
clones that have GRRKLTFDEEAYKN. Hence, we proceeded with clones producing 
antibodies against the peptide, TEALSKLREDFRMQ  (specific for CC3). 
Monoclonal
 
hybridomas were finally obtained through limiting dilution and derived 
antibodies were purified by protein-A-chromatography.   
 
2.1.2 Validation of CC3 monoclonal antibodies  
Positive antibody was confirmed
 
by Western blot and immunohistochemistry analysis 
using HCT116 colorectal cell lines transfected either with empty or CC3 vector, 
encoding the open reading frame of CC3 (kind gift from Emma Shtivelman, 
University of California, San Francisco). The same cell lines were grown on 
coverslips, fixed in methanol and subjected to immunohistochemistry.  Specifically, 
we tested the monoclonal antibody in paraffin-embedded cell pellets, to ascertain it 
would eventually work in similarly processed tissue blocks. For paraffin-embedded 
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cell pellets, HCT116 colorectal cell lines transfected either with empty or CC3 vector 
was grown to 80% confluence, washed with phosphate-buffered saline (PBS) and 
collected by trypsinization. The cells were pelleted down, washed with PBS, then 
fixed with 10% neutral buffered formalin and resuspended in Bacto Agar. The agar 
pellet was processed into paraffin wax. Sections at 4 μm were stained with primary 
antibody and developed as in the immunohistochemistry method described in section 
2.4 
 
2.2 Clinical Specimens 
Fourteen frozen tumor samples consisting of seven stage IIa and seven stage IV 
tumors were obtained through NUH-NUS Tissue Repository for laser capture 
microdissection (section 2.5). Stage IIa samples were chosen due to shortage of Stage 
I frozen tissues. In addition, to examine the expression and localization of CC3 
protein, fourteen matched normal and tumor colorectal tissues paraffin blocks and ten 
matched primary tumor, metastases to lymph node and liver were obtained from 
Department of Pathology, National University of Singapore (NUS). All tissues were 
obtained with patient consent and complied with the regulations set by NUS 
Institutional Review Board (IRB) 
 
2.3 Tissue microarray (TMA) 
Colon tissue microarray was obtained from NUS-NUH tissue repository.  A total of 
ninety-two formalin-fixed, paraffin-embedded colorectal tissue samples were used for 
tissue microarray construction, as described by Kononen et al.(Kononen, Bubendorf 
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et al. 1998) Before arraying, sections from each tissue block were stained with 
Hematoxylin and Eosin (H&E) and a representative area of tumor was defined by 
pathologists. Tissue cylinders with a diameter of 0.6 mm were then punched from the 
targeted tumor area of each donor tissue block and deposited into a recipient block 
using a tissue arraying instrument (Beecher Instruments®, Silver Spring, MD).  
 
In addition, two types of tissue microarray were purchased from US Biomax. One of 
which contains a spectrum of colon diseases, which included 16 adenocarcinoma 
(Not-otherwise-specified), 14 mucinous adenocarcinoma, 35 metastatic 
adenocarcinoma metastasized to lymph nodes and 6 metastatic signet-cell carcinoma 
metastasized to lymph nodes. The other contains 18 chronic inflammation of mucosa, 
16 hyperplasia of glandular epithelium and 9 polyps. 
 
The other array (Cat # MC5002) consists of tumor and normal tissues from multiple 
organs. 
 
2.4 Immunohistochemistry in tissue sections 
4-µm tissue sections or TMA were mounted onto Polysine
TM
 slides (Menzel-Glaser, 
Germany) and deparaffinized with xylene and graded alcohol. Antigen retrieval was 
performed by microwave heating in citrate buffer, pH 6.1 (Dako, USA) for 10 
minutes for CC3, 15 minutes for Bax, followed by endogenous peroxidase activity 
block using 3% H202 in PBS. For Bcl2 and Bcl-xl, antigen retrieval was performed in 
a pressure cooker for 25 minutes in citrate buffer. Tissue sections were incubated with 
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primary antibodies overnight at 4°C. Antibodies used were: 1:100 mouse monoclonal 
CC3, rabbit polyclonal 1:50 Bax (Santa Cruz), mouse monoclonal 1:50 Bcl2 (Santa 
Cruz) and 1:50 Bcl-xl (Santa Cruz).  Detection was carried out by incubation with 
peroxidase-labeled
 
polymer conjugated to secondary antibodies (Envision, DAKO);
 
staining was completed by 5 minutes of incubation with 3,3'-diaminobenzidine
 
according to the manufacturer’s instructions (Envision, DAKO). Tissue sections were 
then counterstained with Gill’s Hematoxylin (Sigma). Positive controls were HCT116 
transfected with CC3 cell pellet block as described in section 2.1.2. Negative controls 
were performed by omitting the primary antibody incubation step. Evaluation of 
immunohistochemistry scoring was analyzed by trained pathologist, Dr Rajeev Singh 
(NUS-NUH Tissue Repository). 
 
2.5 Laser Capture Microdissection (LCM) 
Tissue samples were removed from vials and were embedded into Optimal Cutting 
Temperature (OCT) matrix. The samples were cut into 20 μm thick slices and fixed 
onto single frost microscopic slides (CellPath, Wales UK). The slides with slices were 
fixed using baths of 75%, 95%, and 100% ethanol and xylene. The tissue slices were 
stained lightly with Hematoxylin Solution and Eosin (HistoGene™ LCM Frozen 
Section Staining Kit, Arcturus) for visualization of their morphology. All solutions 
used were RNase and DNase-free. 
 
Extractions of the tumor epithelial cells from the tissue slices were performed with 
the Arcturus PixCell© Laser Capture Microdissection (LCM) Instrument. The tumor 
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cells were identified for LCM capture with the use of H&E slides. The LCM caps 
were lysed in lysis binding buffer by incubating the caps at 60º C for 2 h and kept in -
80 º C for RNA and DNA isolation (section 2.7.1 and 2.11.1). 
 
2.6 Functional study of CC3 in colorectal cell lines 
2.6.1 Cell lines 
Thirteen colorectal cells lines: Colo201, Colo205, Colo320, HT29, SW403, SW480, 
SW620, WiDr, DLD-1, HCT116, LoVo, LS-174-T and RKO were kindly provided 
by Mr Masafumi Inoue (IMCB, Singapore). Eleven breast cancer cell lines: HMEC, 
MCF-10A, MCF-12A, MB157, MB231, MB468, MCF7, SKBr, T47D, BT474 and 
BT549 were purchased from ATCC.  
All colorectal cell cultures and were grown with DMEM (Sigma), supplemented with 
10% Fetal Bovine Serum (Invitrogen) in a humidified incubator (Sanyo) supplied 
with 5% CO2. 
 
2.6.2 Generation of Stable Transfectants Overexpressing CC3 
The plasmid pcDNASCC, encoding the open reading frame of CC3 was kindly
 
provided by Dr. Emma Shtivelman (University of California, San Francisco). 
Transfections
 
were performed using LipofectAMINE 2000 (Invitrogen, Carlsbad,
 
CA) 
as recommended by the manufacturer. Control cells were generated by transfecting 
pcDNA3.1 plasmid (Invitrogen). 1ug of control or CC3 plasmid was used and cells 
were selected in 150 µg/ml (for SW620), 160 µg/ml (for HCT116) 180µg/ml 
(Colo320) of G418 antibiotics (Gibco BRL Life Technologies, Inc) over 14 days.  
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Mixed populations of G418-resistant stable cells were screened with Western Blot 
using CC3 polyclonal antibody (gift from Dr. Emma Shtivelman) and realtime PCR. 
 
2.6.3 siRNA transfection 
Before transfection, 5 x 10
5
 cells per well were plated into 6-well plates and grown 
for 1 day in antibiotic-free medium containing 10% FBS. When the cells were about 
60% confluent, they were transfected with three pre-designed CC3 siRNA (Ambion 
Inc, US) or with a nonspecific negative control siRNA (UUC UCC GAA CGU GUC 
ACG U) using LipofectAMINE 2000 (Invitrogen, USA) according to the 
manufacturer's instructions. In separate experiments, Bcl2 and Bcl-xl siRNA were 
used for transfections. siRNA duplex sequences are as shown in Table 2.1. 
Optimization was performed with varying concentrations of siRNA and incubation 
period. CC3 siRNA #2 was shown to have the best knockdown effect among the three 
siRNAs. The highest knockdown effect was achieved with 20nM of CC3siRNA, 
50nM Bcl2 and 50nM of Bcl-xl. For realtime PCR and further assays, transient 
transfections were performed for 48 hr before harvest. 
 
2.6.4 Cell viability (Trypan Blue exclusion and Cell Titer Blue assay) 
For cell counting assays, 5 x 10
5
 cells were seeded into six-well plates in complete 
medium. Cell
 
viability was determined by Trypan blue
 
dye exclusion assays and 
counting was performed with a hemocytometer. Being a vital stain, Trypan blue 
stains only dead cells, where the membrane is disrupted. 
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Equal number of cells was also seeded in 96-well black plates (Corning Incorporated) 
in triplicates. Relative numbers of viable cells were measured using the fluorometric, 
resazurin-based Cell Titer Blue assay (Promega), according to the manufacturer's 
instructions, at 560Ex/590Em nm in a Tecan microplate reader. 20µl of Cell-Titer Blue 
solution was added per 100µl of media and incubated for four hours at 37
o
C.The 
assay is based on the ability of living cells to convert a redox dye (resazurin) into a 
fluorescent end product (resorufin). Nonviable cells rapidly lose metabolic capacity 
and thus do not generate a fluorescent signal. Statistical analysis of the data was 
performed by Student’s t test, with statistical significance accepted at p < 0.05. Black 
opaque plates reduce unwanted well-to-well interference and hence increased the 
accuracy of fluorescence reading. 
 
2.6.5 Proliferation Assay 
The CyQuant Cell Proliferation Assay Kit (Molecular Probes, Eugene, OR) was used 
for the cell proliferation assay based on fluorescent staining of cellular nucleic acids. 
This assay is based on dye fluorescence enhancement upon binding to cellular nucleic 
acids. Cells were seeded into 96-well flat-bottom tissue culture plates 1 day before 
testing to allow attachment to the bottom overnight. For proliferation, 5000 cells per 
well were seeded. At the end of testing, cells were lysed by 1 cycle of freeze (–80 °C) 
and thaw (room temperature). CyQuant reagents were added (100 µl/well) following 
the manufacturer’s instructions. Fluorescent intensity was read with excitation at 485 




2.6.6 Detection of apoptosis 
2.6.6.1 Flow cytometric DNA content assessment assay using PI/RNAse A 
Control and treated cells were harvested by trysinization (including floating cells), 
fixed in 75% cold Ethanol/PBS, by adding in a drop-wise manner, and kept in 
ethanol/PBS solution for at least 24 hours at 4 
o
C, until further processing. After cells 
were washed with cold sterile PBS buffer, fixed cells were incubated with 50 µg/ml 
Propidium Iodide (PI) and 100 ug/ml RNAse A-I in hypotonic citrate buffer (0.37 g 
sodium citrate/L, 0.15 g sodium chloride/L, and 0.63 g dextrose/L, 0.1% Triton X-
100, pH adjusted to 6.2) for 30 minutes in dark, at room temperature and further 
analyzed by flow cytometry (Becton Dickinson, Franklin Lakes, NJ). Propidium 
iodide binds to double stranded DNA by intercalating between base pairs, but is 
excluded from cells with intact plasma membranes. The relative content of DNA 
indicates the distribution of a population of cells throughout the cell cycle. For 
example, cells in the G0/G1 phases of the cell cycle are diploid, or have a DNA 
content of 2n. Cells within the G2/M phases have a DNA content of 4n. Cells that are 
sub-diploid (<2n) are apoptotic (Sub-G1) can also be quantified using this method. 
All the protocol steps were performed at 4 
o






2.6.6.2 Flow Cytometric Apoptosis Assays with AnnexinV-FITC and 7AAD 
Apoptosis
 
was also determined using the NEXIN
TM
 assay (Guava, Inc.) by double 
staining of the cells with Annexin V-PE/7AAD. Early apoptotic event results in 
exposure of phosphatidylserine on the outer surface of the plasma membrane, which 
can be detected by fluorochrome-labeled annexin V, late apoptotic and necrotic cells 
lose the ability to exclude cationic nucleotide-binding dyes, and nuclear DNA is 
stained with 7-aminoactinomycin D (7-AAD).1X10
5
 cells (both floating and adherent) 
were
 
incubated with the reagent for 30minutes  in the dark, followed by flow 
cytometric analysis by bench-top mini-fluorescence-activated cell sorter (mini-FACS)
 
(GUAVA Technologies) according to the manufacturer's
 
instructions. Each 
experiment was repeated at least twice. 
 
 2.6.6.3 TUNEL (terminal deoxynucleotidyl transferase–mediated nick-end 
labeling). 
Apoptotic cells were also identified by terminal
 
deoxynucleotidyl transferase-
mediated dUTP nick end labeling
 
(TUNEL) staining using DeadEnd Fluorometric 
TUNEL System (Promega Corp., Madison,
 
WI). Apoptosis is characterized by the 
generation of DNA fragments by endogenous endonucleases. TUNEL assay relies on 
the presence of nicks in the DNA which can be identified by terminal 
deoxynucleotidyl transferase, an enzyme that will catalyze the addition of dUTPs that 
are secondarily labeled with fluorescein. Both floating cells and cells growing in a 
monolayer (detached
 
by trypsinization), were pooled, washed in PBS, and fixed in
 
4% 




Vectashield mounting reagent, containing 6-diamidino-2-phenylindole
 
(DAPI; Vector 
Labs). The number of TUNEL-positive cells
 
in a field was examined with an
 
inverted 
Fluorescent Microscope (Nikon, Japan) and
 
photos were taken with a Nikon 35-mm 
camera. Each cell line was examined in triplicate in each
 
experiment and each 
experiment was repeated at least thrice. Cell counting was performed in five random 
microscopic views at a magnification of 20X. Positive controls were generated by 
pre-treatment of fixed cells with DNase 1. This results in fragmentation and exposure 
of multiple 3’-OH DNA ends for labeling. In negative controls, the terminal 
deoxynucleotidyl transferase was not added.  
 
2.6.6.4 DNA laddering 
Floating and adherent cells were lysed in buffer containing 10 mM Tris-HCl, pH 7.4, 
10 mM EDTA, 10 mM NaCl, 0.5% SDS and 0.5 mg/ml proteinase K (40 µl per 10
6
 
cells) overnight at 48°C. RNase A was then added to the mixture adjusted to 5 mg/ml 
and incubated for 3 h at 50°C. The DNA was isolated using phenol/chloroform 
extraction and ethanol precipitation. Pellets were air-dried and re-suspended in 30 µl 
Tris-EDTA buffer. 10ug of DNA from each sample were analyzed by electrophoresis
 





2.6.6.5 Immunofluorescence of anti-Bax in cell lines 
Cells were grown approximately 90% confluence in a four well Lab-Tek™ chamber 
slide system (Nunc, Rochester, NY). The cultures were fixed with neutral buffered 
formalin and washed with PBS. The cells were first incubated with Goat Serum 
(Biogenex, San Ramon CA) for 30minutes for blocking. A primary antibody 
consisting of a 1:1000 dilution of a mouse anti-human monoclonal Bax antibody 
(6A7) (Sigma B8429) (Table2.2), was incubated on the culture slides overnight at 4
o
C. 
The epitope recognized by the antibody resides within amino acids 12-24 of Bax 
hence it is conformation-specific and reacts with Bax of its active/mitochondrial 
conformation. The samples were in washed with PBS and were incubated with a 
1:500 dilution of a secondary antibody for Alexa Fluor 488® Goat 72 Anti-mouse 
(Invitrogen, Carlsbad, CA) for one hour at 37
 o
C. After PBS rinse, slides were 
mounted with Vectashield mounting media (containing DAPI nuclear stain). Images 
of the slides were taken with the Nikon Inverted Fluorescent Microscope.  
 
2.6.7 Caspase 3/7 activity 
Caspase 3/7 activities were assayed by the Caspase-Glo 3/7 Assay kit (Promega Corp., 
Madison,
 
WI), according to the manufacturer's instructions. Briefly, cells were plated 
onto white-walled 96-well plates (2 10
4
 per well). The lyophilized substrate 
(DEVD-aminoluciferin powder) was dissolved in Caspase-Glo 3/7 buffer (lysis buffer) 
and added to the cells. The luminescence was measured (Tecan, Austria) after one 
hour incubation. Values were expressed as the ratio between luminescence signals 
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generated in CC3 vector cells and those produced in empty vector cells. Each value 
was obtained from three independent experiments carried out in triplicate. 
 
2.6.8 Anchorage independence in “soft agar” assay 
For anchorage dependent growth assays, 5 x 10
5
 cells were seeded per well (in 
triplicate)
 
in six-well plates in growth medium containing 0.4% low melt point (LMP) 
agarose
 
(BRL Life Technologies, US) onto a bottom layer of 0.6% (LMP) in
 
growth 
medium. Following 14 days of incubation at 37°C,
 
colonies >200 µm in diameter 
were counted. The plates were stained with crystal violet and colonies were counted 
on ChemiDoc XRS instrument (Bio-Rad, Hercules, CA). 
 
2.6.9 In vitro invasion assay 
Invasion assays were done using modified
 
Boyden chambers with filter inserts for 24-
well dishes containing
 
8-µm pores (Corning Incorporated, US). Matrigel
 
(40 µg, BD 
Biosciences, US)–coated filters were used for invasion assays. HCT116 empty or 
CC3 transfected cells (5.0 x 10
5
) were plated into 100 µl of serum free
 
DMEM in the 
upper chamber, and the lower chamber was filled
 
with 0.5 ml of DMEM 
supplemented with 10%FBS. After 48 hours in culture, cells were fixed
 
in methanol 
for 15 minutes and stained with 0.05% crystal violet
 
in PBS for 15 minutes. Cells on 
the upper side of the filters
 
were removed with cotton-tipped swabs, and the filters 
were
 
washed in PBS. Cells on the underside of the filters were viewed
 
and counted 
under a light microscope (Nikon, Japan) at 40X magnification. Each cell line was 
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plated in triplicate in each
 




2.6.10 Wound Healing assay 
Confluent
 
cell monolayers were manually wounded by scraping the cells
 
with a 
pipette tip to perform wound healing assays. Wound size
 
was verified under a 
microscope to ensure that all wounds were
 
the same width. The cell culture medium 
was then replaced with
 
fresh medium, and wound closure was monitored by 
microscopy
 
every 24 h. 
 
2.7 RNA Isolation 
2.7.1 RNA Isolation from Laser captured cells 
Cells were first isolated by Arcturus® PicoPure® RNA Isolation and RNA 
concentration was measured by BioRad Experion automated electrophoresis station 
for accuracy. 100ng of RNA from each tissue sample went through two rounds of 
amplification, using MessageAmp II aRNA kit (Ambion, Austin, USA), an in-vitro 
transcription based amplification to obtain a higher yield of amplified RNA (aRNA). 
It has been shown by Van Gelder et al. that the spectrum of aRNA produced during 
amplification by this method qualitatively reflects the population of cDNA from 





2.7.2 RNA Isolation from cell lines 
Total RNA was extracted from cell lines by TRI reagent (Molecular Research Center, 
Inc), according to manufacturer’s protocol. Briefly, Tri reagent was added to cells 
grown at 80-90% confluence for cell lysis in a proportional volume, ie. 2.5ml of Tri-
reagent was added to 25cm
3
 flasks. Subsequently, the homogenate was centrifuged at 
12,000 x g at 4°C for ten minutes to remove insoluble materials. The supernatant 
containing the RNA was transferred to a fresh tube and 0.2ml of chloroform was 
added per 1ml Trizol reagent. The tubes were shaken vigorously for 15 seconds and 
centrifuged again at 12,000 x g at 4°C for 15 minutes. RNA remained exclusively in 
the aqueous phase and was transferred to a fresh tube. Interphase was stored at -80°C 
for carrying out DNA isolation later. RNA was precipitated by the addition of 0.5ml 
isopropanol per 1ml Trizol reagent used. The sample was centrifuged again at 12,000 
x g at 4°C for 10 minutes. RNA pellet was formed at the side and bottom of the tube. 
Thereafter, the pellet was washed with 75% ethanol and centrifuged at 7,500 x g at 
4°C for five minutes. The RNA pellet was air-dried, solubilized in 50µl diethyl 
pyrocarbonate (DEPC) water and incubated at 55°C for ten minutes. Finally, 
dissolved RNA was quantified spectrophotometrically at 260nm (Eppendorff). 
Thereafter, the extracted RNA was stored in -80°C for reverse transcriptase-
polymerase chain reaction (RT-PCR) for future use. 
 
2.8 cDNA synthesis 
Reverse transcription was performed on 1 µg of total RNA or 200ng of aRNA with 
0.5µg of Oligo(dT)15 Primers and ImProm-II™ Reverse Transcription System 
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(Promega Corp., Madison, WI). 1μg of RNA was transcribed in a total volume of 
20μl, containing 1X Reverse Transcriptase (RT) buffer, 3mM MgCl2, 0.5mM dNTP, 
20 units of RNase inhibitor and 1unit of reverse transcriptase. The samples were 
incubated at 25
o
C for 5min and 42
 o
C for 1hour. Finally, RT was inactivated by 
heating at 70
 o
C for 15min. 
 
2.9 Real time PCR amplification 
The cDNA template (100ng) obtained from reverse transcription was amplified in a 
realtime thermocycler (ABI Prism 7500) using specific primers and probes as shown 
in Table 2.1. For LCM samples, a multiplex PCR, using Taqman assay was 
performed. For samples extracted from cell lines, SyBr green assay (Applied 
Biosystems, Foster City, CA) was performed. 200nM of forward or reverse primers 
and 100nM of probes were used for realtime PCR reaction. GAPDH or β-actin was 
used as an endogenous control for normalization. In negative controls, template was 
replaced by an equivalent volume of water.  
 
Results were analyzed using the comparative Ct method(Livak and Schmittgen 2001). 
Delta Ct was obtained by subtracting the Ct of the endogenous control from the target 
sequence Ct. Delta delta Ct is the difference between the delta Ct of different samples. 
Fold difference is calculated as 2- 
Delta delta Ct
. Ct and relative quantification was 
calculated using the supplied software. Thermocycling conditions are as follows: 
initial denaturation at 95
o
C for 10minutes, followed by 40 cycles of denaturation at 
95
o
C for 30seconds, annealing and extension at 68
o
C for 32seconds. The annealing 
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temperatures of primers are shown in Table 2.1. For SyBr Green assays, a melt curve 





C. This ensures that there is a specific product if the melt 
curve shows only a single peak. 
 
2.10 Semi-quantitative PCR amplification 
The cDNA template (100ng) obtained from the reverse transcription was amplified in 
a thermocycler (Eppendorff) using specific primers as shown in Table2.1. All PCR 
primers were synthesized by 1
st
 Base (Singapore) facility. Sequences were analyzed 
using BLAST at NCBI website to confirm that they were of the right product size. 
Beta-actin was used as an internal standard for normalization. Master mix (Promega, 
Inc) was prepared for each PCR run, containing 1X GoTaq
®
 Reaction Buffer, 1.5mM 
MgCl2, 200nM forward and reverse primers, 1unit of DNA polymerase in a total 
volume of 50µl. The thermocycling conditions were as follows: an initial denaturation 
of 94°C for 2minutes, three-step PCR of denaturing (94°C for 30 seconds), annealing 
(Table 2.1) and extension (72°C for 30 seconds) was carried out. PCR product 
amplification was in the linear range and the plateau phase was not achieved yet. For 
sequencing reactions, Advantage 2 (Clontech) proofreading enzyme was used with an 
initial denaturation of 94°C for 5 minutes and extension temperature was 68°C. Upon 
the completion of PCR, the products were then run and separated by agarose gel 
electrophoresis. Agarose gel was prepared with addition of 0.001% of ethidium 
bromide. Equal volumes of sample product were loaded into each well and 
electrophoresis (Biorad systems) was conducted at 100mV. 1kb or 100bp DNA 
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markers (i-DNA Biotechnology, Singapore) were loaded on the same gel to ensure 
that PCR products were of the right size. The agarose gel was then visualized on 







Table 2.1 Nucleotide (Primer and siRNA duplex) sequences 





5'-CCT TTT CTA CTT TGT CAG CAA-3' 





5'-GCC CTG TGG ATG ACT GAG TA-3' 





5'-GCA GGT ATT GGT GAG TCG G-3' 





5'-GTG AAT TTC CCC AAG CAT GGC CGA A-3' 





5'-GTG AAT CAA GAA GTG GTG GAC TTT G-3' 





5'-ACA TGG AAG CGA ATC AAT GGA CTC-3' 





5'-CCG CAA AGG AAG CAA GAA-3' 





5'-GCT CTT CCT TTG TTC ATC-3' 





5'-TAC ACA GAC GTG TCC AAC ATG GGC-3' 





5'-GAG GAA GCT GCT AAG GAC TAG TTC-3' 





5'-GAT CCA GGT TAT CCC AAA ATG A-3' 





5'-CTC CTT AAT GTC ACG CAG AT-3' 




5'-GTG AAT CAA GAA GTG GTG GAC TTTG-3' 
5'-CTT  CAG CAC ATA ATC TCG GTC AAC-3' 




5'-CGA AAC TAC CTT CAA CTC CAT CATG-3' 
5'CCA GGG CAG TGA TCT CCT TCTG--3' 




5'-CGA CAG TCA GCC GCA TCT TC-3' 
5'-CGC CCA ATA CGA CCA AAT CCG-3' 
Probe 5'-TGC CCA GCC GAG CCA CAT CGC T-' 
CC3 Exon3 
Nested 1 Sequencing 
60 
5'-GGC CTC CCA GCC TGC TAC-3' 
5'-GTA CTG CCA AAA TAG CTAG-3' 






5'-GCT ACC CAA GCC AAG TAG TAA TC-3' 




5'-TTT AAG AGA GGT TAGGAA TAG GTT G-3' 
 5'-AAA ACA TCC CAC CTT CCC TAA T-3' 
M13 Sequencing  5'-CAG GAA ACA GCT ATG ACC-3' 




5'-TAG CGT CGT CGC GAG GTT ATT CG-3' 




5'-GTA GTG TTG TTG TGA GGT TAT TTG G-3' 
 5'-CAC AAC ACA ACA AAA ACA AAA CAA CC-3' 
CC3 siRNA #1 
Transient 
Silencing 
Sense 5'-CCA AAU CGG UAA UUU CAG Gtt-3' 
Targets Exon 6 
Anti-
sense 5'-CCU GAA AUU ACC GAU UUG Gtg-3' 
CC3 siRNA #2 
Transient 
Silencing 
Sense 5'-GCC UGG UUA UAC AUA UAG Att-3' 
Targets Exon 6 
Anti-
sense 5'-UCU AUA UGU AUA ACC AGG Ctc-3' 
53 
 
CC3 siRNA #3 
Transient 
Silencing 
Sense 5'-CCG GCA GAG UGC UCU UAA Att-3' 
Targets Exon 2 
Anti-




Silencing Sense 5'-UUU UCC GAA CGU GUC ACG UTT-3' 
 
Anti-
sense 5'-ACG UGA CAC GUU CGG AGA ATT-3' 
Bcl2 siRNA Transient 
Silencing 
Sense 5'-AGU ACA UCC AUU AUA AGC U-3' 
Anti-
sense 5'-AGC UUA UAA UGG AUG UAC U-3' 
Bcl-xl siRNA Transient 
Silencing 
Sense 5'-CAG GGA CAG CAU AUC AGA G-3' 
Anti-
sense 5'-CUC UGA UAU GCU GUC CCU G-3' 
 
 
2.11 DNA Isolation 
2.11.1 DNA Isolation from Laser captured cells 
Genomic DNA was captured from five paraffin-embedded colorectal cancer sections 
using Arcturus PixCell© Laser Capture Microdissection instrument. DNA was 
extracted using PicoPure DNA Extraction Kit (Arcturus Bioscience, Mountain View, 
CA, USA) and quantified using Invitrogen PicoGreen DNA quantitation kit. This 
assay contains a dye which binds to only double stranded nucleic acids hence reduces 
interference from RNA or single-stranded DNA. 
 
2.11.2 DNA Isolation from cell lines 
The interphase left from RNA isolation (Section 2.7.2) was used for DNA isolation 
with DNAzol reagent (Molecular Research Center, Inc). 0.3ml of absolute ethanol 
was added to precipitate the mixture and centrifuged at 12,000g for five minutes. The 
pellet was dissolved in 1mL of DNAzol and 0.25μl of Proteinase K and incubated at 
55°C overnight with shaking. 1mL of Phenol / Chloroform (1:1) was added to the 
clear solution, vortexed and centrifuged at 12,000g for fifteen minutes. The upper 
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layer of the solution was transferred to a new tube. Next, 0.5ml of absolute ethanol 
was added and stored for five minutes at room temperature. It was then spun at 
12,000g for fifteen minutes at 4°C to pellet the precipitated DNA. Next, DNA pellet 
was washed with 1mL 75% ethanol twice, spun at 5,000g for ten minutes at 4°C 
before the supernatant was discarded and left to air dry for five minutes. The pellet 
was then dissolved in 50μl 8mM NaOH and the pH adjusted to pH 8.0 by addition of 
0.1M HEPES. DNA concentration was quantified with a spectrophotometer 
(Eppendorff) at 260nm and stored at -80°C until further use. 
 
2.12 Protein extraction 
2.12.1 Total proteins 
The cells were harvested by trypsinization, washed with PBS and lysed with M-PER 
mammalian protein extraction reagent (Pierce) supplemented with Complete
 
Mini 
EDTA-free protease inhibitors (Roche Applied Science). 
 
2.12.2 Subcellular fractionation 
For the analysis of the mitochondrial apoptosis pathway, cells were lysed and protein 
was fractionated with a Mitochondrial Extraction Kit (Pierce) to generate 
mitochondrial and cytoplasmic fractions. The whole process was conducted on ice or 
4
 o
C to prevent mitochondrial membrane disruption. Similarly, protease inhibitors 
were added to both cytoplasmic and mitochondria fractions. Mitochondrial fractions 
were stored in aliquots in -80
o
C to ensure minimum disruption of mitochondrial 




To ensure equal loading, sample protein concentrations were measured by BCA 
protein assay kit (Pierce Biotechnology, Rockford, IL) according to manufacturer’s 
protocol. For protein concentration determination, a standard curve was generated 
using serial dilutions of Bovine Serum Albumin (BSA). For total proteins or 
cytoplasmic proteins, 40µg/lane and 20µg/lane of mitochondrial proteins were boiled 
for 5minutes loaded into 10well gels.  
 
2.13 Western Blotting and Immunodetection 
Proteins were separated on 7-15% SDS-PAGE gels using Mini-PROTEAN 3 
Electrophoresis Cells (Bio-Rad, Hercules, CA, USA) at 70V for 30min and 85V until 
the dye front reached the edge of the gel. The proteins were transferred onto Hybond-
Polyvinylidene Fluoride (PVDF) membrane (GE Healthcare, Little Chalfont, Bucks, 
UK) using the wet apparatus (Bio-Rad, Hercules, CA) at 110V for 1hr. The 
membranes were blocked with 5% non-fat milk (Santa Cruz Biotechnology) in Tris-
buffered saline containing 0.1% Tween-20 (TBS-T) and incubated overnight with the 
respective antibodies (Table 2.2) at 4ºC. One of the following secondary antibodies 
was used –  HRP-conjugated goat anti-mouse IgG (Molecular Probes, Invitrogen, 
Oregon, USA) at 1:5000 dilutions in TBS-T, HRP-conjugated goat anti-rabbit IgG 
(ZYMED  Laboratories Inc, San Francisco) at 1: 10 000 dilutions in TBS-T. 
Secondary antibodies were applied for 1 hr after washing off any unbound primary 
antibodies. The chemiluminescent signals were detected using SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL, USA). Signals were captured with 
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the ChemiDoc System (BioRad, Hercules, CA). The same membrane was reprobed 
with an antibody for β-actin to control for protein loading and transfer. 
 
Table 2.2 List of antibodies used for western blot 
Antibody Purpose Source 
AIF (H300) WB 
Santa 
Cruz 
Bax (N-20) WB, IHC 
Santa 
Cruz 
Bax (6A7) IF Sigma 
Bcl2 (C2) IHC 
Santa 
Cruz 
Bcl-xl (H5) IHC 
Santa 
Cruz 
Smac (2D12) WB 
Santa 
Cruz 
Caspase 3 WB 
Cell 
Signaling 
Caspase 9 WB 
Cell 
Signaling 






VDAC WB Sigma 
XIAP (117320) WB 
R&D 
Systems 









2.14 Sequencing of CC3 Exon 3 
In order to identify if there are mutations in CC3 gene sequence, we performed 
sequencing in a panel of colorectal and breast cancer cell lines as well as laser 
captured genomic DNA from five colorectal tissues samples.  Exon 3 on CC3 has 
been shown to be crucial as the amino acid sequences encoded by exon
 
3 are 
conserved among human, mouse, and Caenorhabditis elegans.
 
 This region of the 
CC3 protein is important for the nuclear
 
localization(Ito, Jiang et al. 2003). Exon 3 of 
the CC3 gene was amplified with Advantage 2 (Clontech, Japan).  The primers used 
for
 
amplification were 5'-GGCCTCCCAGCCTGCTAC-3' and 5'-
GTACTGCCAAAATAGCTAG-3'.
 




as shown in Table 2.1. The first reactions were carried
 
out for 25 cycles of 94°C, 30 s; 
60°C, 30; and 72°C,
 
30 s. The nesting PCR reactions were carried out for 32 cycles
 
of 
94°C, 30 s; 60°C, 30; and 72°C, 30 s. Equal amounts of DNA samples were subjected 
to amplification by the first pair of primers and separated by agarose gel 
electrophoresis to ensure that they were of the correct size. The PCR band was then 
excised and purified by Wizard® SV Gel and PCR Clean-Up System. Both the nested 








2.15 Drug preparation 





5-Aza-2′-deoxycytidine (Sigma) was dissolved in DMSO at 10µM and stored as 
aliquots in -80
 o
C. As 5-Aza-dC is chemically unstable, aliquots which were thawed 
and unused were discarded.  
 




Drugs were prepared freshly, every three months or as needed. 
 
For control treatments, equal volume of DMSO was used. 
 
In combination studies, 5-Aza-2′-deoxycytidine and 5-fluorouracil were added 
sequentially, while scrambled and CC3 siRNAs were added together with 5-Aza-dC 
treatments.  
 
2.16 Methylation studies on CC3 promoter in colorectal cell lines 
2.16.1 CpG island and promoter analysis 
A 10kb region of genomic sequence encompassing the CC3 gene (GenBank 
NM_006410) including 1kb flanking the 5’-end of the gene was examined. This 
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sequence was entered into the Genomatix promoter prediction program 
―PromoterInspector‖(Scherf, Klingenhoff et al. 2000), or into Methprimer 
(http://www.urogene.org/methprimer/index1.html) for analysis of CpG dinucleotide 
content and CpG island identification(Li and Dahiya 2002). CpG islands were defined 
as regions of DNA greater than 200 base pairs, containing a guanine/cytosine content 
greater than 50% and an observed to expected CpG ratio above 0.6. 
 
2.16.2 Bisulfite Treatment  
Sodium bisulfite modification of isolated genomic DNA was processed by spin 
column using EZ DNA Methylation-Gold Kit™ (Zymo Research) according to the 
manufacturer’s instructions. In the bisulfite reaction, all unmethylated cytosines were 
deaminated and converted to uracils, whereas 5-methyl cytosines remained unaltered. 
1µg of genomic DNA was used in each bisulfite conversion reaction and recovered in 
20μl of elution buffer. The resulting bisulfite-treated DNA was stored in 5μl aliquots 
at -80˚C for a maximum of one week when not used immediately. 
 
2.16.3 TA cloning and sequencing 
Bisulfite-converted genomic DNA was subjected to bisulfite sequencing PCR(BSP) 
using primers (Table 2.1). PCR was performed using a proofreading polymerase, 
Advantage® 2 Polymerase Mix (Clontech, Japan), which increased fidelity of the 
reaction. PCR products obtained with these primers were subcloned into pGEM®-T 




Vector and PCR product ratios were optimized at a ratio of 1:9 or water as a control, 
and was incubated with T4 Ligase at 16°C for 18 hours. Subsequently, the ligation 
mix was transformed into E. coli K12 JM109 chemically competent cells (Promega 
Corp.)  by heat-shock method (42°C) for exactly 2min. Cells were allowed to recover 
LB broth for 2 hours at 37°C and plated in dilution to Luria Bertani  (LB) agar 
contained ampicillin (100ug/ml) in the presence of X-gal (1µg) and IPTG (2µg) 
overnight.  
 
2.16.4 Colony PCR screening 
Resultant white colonies (Ten to 15 clones per PCR product) were randomly selected, 
boiled in 50µl of water for 5 min, centrifuged at 12, 000g. The resultant supernatant 
(2µl) was added to a PCR reaction using CC3 BSP forward primer and M13 reverse 
primer pair to screen for the appropriate insert size (Table 2.1). Using one primer 
from the plasmid and one from the PCR product as compared to using primers for 
PCR products reduces false positive clones. False positive clones may sometimes 
derive from LB agar that contains trace amounts of un-ligated insert DNA(Dallas-
Yang, Jiang et al. 1998). 
 
Bacterial cultures that contain plasmids of the correct insert size (~435 base pairs) 
were cultured overnight and plasmids were extracted using Wizard
®
 Plus Minipreps 
DNA Purification System (Promega). Finally, plasmids were sequenced with an M13 
reverse sequencing primer using Big Dye Terminator v3.1 (Applied Biosystems, 
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Foster City, CA). Sequencing reactions were conducted 1
st
 Base (Singapore) core 
facilities.  
 
 2.16.5 Methylation-Specific PCR (MSP) 
The same bisulfite-converted genomic DNA was subjected to MSP and primers are 
shown in Table 2.1. The U primer sets were annealed to unmethylated DNA that had 
undergone chemical modification, whereas M primer sets were annealed to modified, 
methylated DNA. The sensitivity of these primers in detecting unmethylated and 
methylated CC3promoter has previously been demonstrated(Tong, Li et al. 2009). 






3.1 Novel monoclonal CC3 antibody is specific 
We employed three techniques to ascertain the specificity of our novel monoclonal 
antibody. HCT116, which expresses low levels of CC3, was used for transfection 
with empty vector and CC3 vector. Western blot analysis demonstrated that the 
monoclonal antibody detected CC3 at about 30kDa, as indicated by the protein ladder 
and did not detect non-specific proteins (Figure 3.1a). This was compared to 
polyclonal antibodies, which showed a number of non-specific bands (Figure 3.1b). 
Next, immunohistochemistry was performed on cells grown on coverslips. Similarly, 
there was strong staining for CC3 over-expressing HCT116 cells (Figure 3.1d) as 
compared to the empty vector controls (Figure 3.1c) and the staining was cytoplasmic. 
To determine whether our antibody would be suitable for immunohistochemistry on 
formalin-fixed paraffin-embedded tissues, we performed immunohistochemical 
staining on HCT116 cells that had been transfected with either empty vector or CC3 
vector.  For the immunohistochemical analysis, cells were pelleted, embedded in 
bacter-agar, formalin fixed, paraffin-embedded, and then sectioned on a microtome to 
produce mock-histological sections. After rehydration and antigen retrieval steps, 
immunostained sections showed strong specific cytoplasmic staining for CC3-
transfected cell pellet and negative staining for empty vector control (Figure 3.1e and 
f). These results demonstrate the specificity of our monoclonal antibody and its 




Figure 3.1 Validation of CC3 monoclonal antibody by (a) Western Blot using 
monoclonal CC3 antibody. HCT116 parental cell line (lane 1), HCT116 empty vector 
transfected cells (lane 2), HCT116 CC3 transfected cells (lane 3). (b) Comparison 
with a polyclonal antibody. HCT116 parental cell line (lane 1), HCT116 empty vector 
transfected cell line (lane 2), HCT116 CC3 transfected cell line (lane 3). M r values of 
the molecular weight markers are indicated on the left (kDa). Immunoperoxidase 
staining of HCT116 (c) empty vector transfected cells and (d) CC3 vector transfected 
cells cultured on coverslips. Immunoperoxidase staining of agar-embedded formalin-
fixed cell pellet sections of HCT116 (e) empty vector transfected cells and (f) CC3 
vector transfected cells. The monoclonal antibody showed negative staining in empty 
vector transfected HCT116 cells, whereas strong cytoplasmic staining was seen on 






3.2 CC3 is expressed on the tips of normal colon mucosa 
Having established the specificity of CC3 monoclonal antibody, we examined the 
expression and localization of CC3 in both normal and tumor tissues. In normal 
mucosa, the distribution of CC3 protein showed a distinct pattern of spatial polarity 
within the crypt. There is strong CC3 staining at the luminal surface of the crypt and 
negative staining at the base (Figure 3.2). This is consistent with its function as a pro-
apoptotic protein where cells are the surface epithelium are committed to cell death 
and shed into the lumen. This result is also similar to a recent finding by Lindfors et 
al(Lindfors, Halttunen et al. 2001), where they found positive CC3 staining at the 
villus tips of normal jejunum. 
  
 
Figure 3.2 Immunostaining of normal colon tissue. Staining is exclusive to the 





3.3 Mucinous carcinomas show decreased CC3 expression 
To investigate the expression of CC3 in different cancer subtypes, we performed 
immunohistochemstry on TMA with adenocarcinoma, not otherwise specified (NOS) 
or of mucinous subtype. Examples of negative, weak and strong staining are shown in 
Figure 3.3a to 3.3d  In adenocarcinoma, NOS, 6/16 showed negative staining, 4/16 
showed weak staining and 6/16 exhibited strong CC3 staining. In contrast, CC3 was 
negative for all 14 cases of mucinous adenocarcinoma (P<0.001, Table 3.1). In 
addition, comparing tumors which metastasized to lymph nodes, there was a 
significant difference between signet-ring carcinomas (also a subset of mucinous 




Table3.1 Immunohistochemistry of CC3 expression in colorectal cancer tissue array 




No Staining Weak  Strong 
Adenocarcinoma 6 4 6 <0.001 
Mucinous Carcinoma 14 0 0   
 
Metastatic Cancer Subtype 
CC3 Staining 
p value* 
No Staining Weak  Strong 
Metastatic adenocarcinoma 
of lymph node 12 15 8 0.010 
Metastatic signet-ring cell 
carcinoma of lymph node 6 0 0   
 
Colon disease spectrum 
CC3 Staining 
p value* 
No Staining Weak  Strong 
Inflammation 3 10 5 0.001 
Hyperplasia 12 2 2  
Polyps 8 1 0   





Figure 3.3 Immunohistochemistry on TMAs of colorectal cancer tissues 
 
Photographs show examples of (a) strong, (b) weak and (c) negative CC3 staining of 
adenocarinoma, NOS. An example of a mucinous adenocarcinoma with negative CC3 







3.4 Downregulation of CC3 expression is associated with colon cancer 
progression 
In another set of TMA from randomly selected colon cancer patients obtained from 
NUS-NUH Tissue Repository, CC3 expression was associated with TMN staging 
(chi-square test, P=0.022). Age, gender and tumor sizes were not associated with CC3 
expression (Table 3.2). In addition, we obtained 10 matched primary tumors, 
metastases to lymph node and to liver from the same patient. There was strong 
cytoplasmic staining in both the primary tumor as well as metastases to lymph. 
However, metastases to liver were negative for CC3 expression (Fig. 3.4a to 3.4c). 
Hepatocytes were positively stained for CC3 as reported by Ito(Ito, Jiang et al. 2003)  
 
Table 3.2 Association between clinicopathologic characteristics of colon cancer 
patients and CC3 expression 
Parameters 
CC3 Staining 
p value No to weak 
staining Strong 
Age    
<= 55 15 9 0.846 
> 55 44 24  
Gender    
Male 31 16 0.707 
Female 28 17  
Tumor Size    
<5cm 31 13 0.108 
>=5cm 26 22  
TMN Staging    
1 and 2 14 17 0.023 
3 22 9  
4 23 7   




Figure 3.4 Matched primary tumor, metastases to lymph node and metastases to 
liver.  
In (a) primary tumor and (b) metastases to the lymph, CC3 is strong. In (c) 
metastases to the liver, cells are negatively stained for CC3 (black arrowhead). 








3.4 Immunohistochemical analysis of CC3 in human normal and tumor tissues   
To our knowledge, all the publications, to-date, are cancer-specific, except for one 
study by Shtivelman(Shtivelman 1997), who reported a ubiquitous expression in 
many tissue types by Northern blot. To further expand our knowledge in the 
differential expression of CC3 in tumor and normal tissues, the in situ locations of the 
CC3 protein were studied by an immunohistochemical approach using paraffin-
embedded human tissues on a commercial tissue microarray.  
 
In most types of cells, CC3 immunoreactivity was cytosolic. Similar to previous 
knowledge, CC3 expression is ubiquitous in all the tissue types in our array although 
the degree of expression varied widely. Even though CC3 has been described as a 
tumor suppressor in many cancers, it appears that it may have an opposite function in 
some other cancers. Low levels of CC3 expression have been reported  in 
hepatocellular carcinoma(Ito, Jiang et al. 2003), lung(Shtivelman 1997; Tong, Li et al. 
2009), gastric and metastatic breast cancer(Zhao, Ni et al. 2007) as compared to 
corresponding normal tissues. However, in contrast CC3 expression has been found 
to be increased in metastatic prostate cancers(Zhang, Zhang et al. 2008).  It is also 
increased in breast cancers which show increased expression of the Her-2/neu proto-
oncogene, which is an adverse prognostic factor(Zhang, Wong et al. 2005). Despite 
the apparent dichotomy functions in different cancers, CC3 has been termed as a 
tumor suppressor based on historical reasons, as it was first identified as a putative 




Table 3.3 summarizes the results for all human tissues, and Figure 3.4.1 shows some 
representative immunostaining results. All the immunostaining was conducted with 
positive control sections of pelleted CC3 -transfected HCT116 cells (prepared as 
described in section 2.4). The same sections provided negative controls, when the 
























Table 3.3 Immunohistochemistry of CC3 expression in various tumor and normal 
cancer tissue array and association with cancer subtype. Immunostaining was scored 
as follows: CC3 intensity 1: weakly positive; 2: moderate and 3: strong intensity. 







p value  
(vs 
normal) 1 2 3 
Brain Normal 5 3 2 0 
 
 
Astrocytoma 11 0 7 3 0.018 
 
Glioblastoma 6 0 4 1 0.097 
       Lung Normal 16 0 15 1 
 
 
Adenocarcinoma 10 4 6 0 0.019 
 
Large cell carcinoma 3 0 3 0 0.49 
 
Small cell carcinoma 5 5 0 0 0.007 
 
Squamous cell carcinoma 9 7 2 0 0.0002 
       Skin Normal 4 1 3 0 
 
 
Malignant melanoma 19 0 13 6 0.049 
 
Squamous cell carcinoma 5 0 3 2 0.232 
       Thyroid Normal 5 5 0 0 
 
 
Follicular carcinoma 10 0 3 7 0.001 
 
Papillary carcinoma 10 0 3 7 0.001 
       Lymph 
node Normal 10 4 5 1 
 
 
Diffuse B cell lymphoma 9 5 4 0 0.217 
 
Hodgkin's disease 9 7 2 0 0.556 
       Breast Normal 4 2 2 0 
 
 
Invasive ductal carcinoma 
(NOS) 41 7 26 8 0.239 
       
       Gastrointestinal tract 
     Liver Normal 5 0 4 1 
 
 
Hepatocellular carcinoma 19 8 11 0 0.045 
       
       Stomach Normal 5 1 4 0 
 
 
Adenocarcinoma 17 6 11 0 0.518 
73 
 





CC3 intensity p value  
(vs 
normal) 1 2 3 
 
    
 
    
 Gastrointestinal tract 
     Pancreas Normal 5 3 1 1 
 
 
Duct adenocarcinoma 16 2 14 0 0.01 
       
       Urinary 
      Kidney Normal 5 0 0 5 
 
 
Clear cell carcinoma 10 1 6 3 0.038 
 
Granular cell carcinoma 8 0 3 5 0.118 
       Bladder Normal 4 0 3 1 
 
 
Transitional cell carcinoma 20 5 9 6 0.443 
       Reproductive 
     Male 





6 29 18 0.02 
       Testis Normal 5 0 5 0 
 
 
Seminoma 13 9 4 0 0.009 
 
Embryonal carcinoma 3 2 1 0 0.035 
       Female 
      Ovary Normal 3 2 1 0 
 
 
Serous papillary carcinoma 14 4 10 1 0.396 
 
Mucous papillary carcinoma 3 1 2 0 0.414 
 
Serous cystadenocarcinoma 1 0 1 0 
 
 
Mucinous cystadenoma 1 1 0 0 
 
 
Endometrioid carcinoma 1 1 0 0 
 




endometrium 19 3 14 2 0.619 




AC=Adenocarcinoma, SCC, Squamous cell carcinoma, LCLC-Large cell lung carcinoma, 
SCLC=Small cell lung carcinoma, MM=Malignant melanoma, FC=Follicular carcinoma, 
Normal brain Astrocytoma Glioblastoma 
Normal lung AC LCLC SCLC SCC 
Normal lymph node DBCL Hodgkin’s 
Normal skin 
MM SCC 
Normal thyroid FC PC 
Normal breast IDC IDC 
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PC=Papillary carcinoma, DBCL= Diffuse B-cell Lymphoma, IDC=Invasive ductal carcinoma, 
Scale bars= 50 μm 
 
HCC=Hepatocellular carcinoma, AC=Adenocarcinoma, CCC=Clear cell carcinoma, 
GCC=Granular cell carcinoma. Scale bars= 50 μm 
Normal liver HCC 
Normal gastric 
Normal gastric AC 
Normal pancreas 
Normal kidney 





TCC=Transitional cell carcinoma, AC=Adenocarcinoma, EC=Embryonal Carcinoma. 
















PC=Papillary carcinoma, CA=Cystadenocarcinoma, EnC= Endometrioid carcinoma, 
AC=Adenocarcinoma. Scale bars= 50 μm 
 










Normal ovary Serous PC Mucous PC Serous CA EnC 




3.5 Selection of Cells with LCM in Tumor Tissues 
To complement our IHC data, we were also interested to assess the mRNA expression 
at different stages in colorectal cancer progression. As shown in Table 3.2, there was 
a significant difference in the TMN staging of colorectal cancer, hence we picked 
seven Stage 2a and seven Stage 4 samples for RNA analyses. Normal mucosa was 
excluded in this study due to technical difficulties in obtaining cells, which were 
specifically at the tips of epithelial cells. To minimize contamination of stromal cell 
RNA in our analyses, the RNA of each sample was selectively isolated using laser 
microdissected tumor cells. The LCM microscope is able to selectively remove the 
desired tumor cells (Figure 3.5c) from the slide leaving stromal and other unwanted 
cells on the tissue slice behind (Figure 3.5b). With the laser of the microscope, the 
cells were affixed to the plastic LCM caps. The cells were removed from the LCM 
caps with lysis binding buffer and the lysed cells released the RNA for isolation. 
Gene expression analyzed by Taqman assay showed that Stage 4 cells had lower CC3 
mRNA levels compared to Stage 2a cells, in general. Similarly, Stage 4 cells had 






















































Figure 3.5 H&E and LCM of the Tumor Colorectal Samples.  
Tumor cells were isolated with the use of H&E staining and LCM capture.  
(a) Tumor tissue was stained with H & E prior to LCM capture. (b) Section of the 
same tumor sample after LCM capture. (c) Tumor cells attached to the LCM cap after 
capture. (d) Realtime PCR of LCM cells showing CC3 expression (top) as well as 
Bcl-2 expression (bottom). Results are an average of 4 independent experiments and 
expressed as means ± SD. 
 
 
3.6 Sequencing of CC3 exon 3 in colorectal cancer tissues, cell lines and breast 
cancer cell lines  
The only report of CC3 mutation was found in exon 3. G134V mutation results in a 
reduced half-life of CC3 while a R106H mutation prevents nuclear transport of CC3. 
To determine if similar mutations may be observed in colorectal cancer, we 
sequenced the DNA of 5 colorectal cancer tissues, extracted by laser microdissection, 
13 colorectal and 11 breast cancer cell lines. We did not find any mutations in exon 3. 
This suggests that CC3 mutation may be a rare event in colorectal and breast cancers, 
similar to two other reports that had not found any mutations in breast cancers(Zhang, 















































3.7 Expression CC3 in 13 colorectal cell lines  
To investigate functional role of CC3, we first examined CC3 expression in 13 
colorectal cell lines, by both real time PCR (Fig. 3.6a) and western blot (Fig. 3.6b). 
We noted that SW480 was established from a primary colon adenocarcinoma and 
SW620 was established one year later from a lymph node metastasis of the same 
patient(Leibovitz, Stinson et al. 1976). mRNA expression of CC3 was significantly 
lower in SW620 compared to the primary tumor-derived cell line SW480. Colo 201 
and Colo 205 were established from ascites of the same patient(Semple, Quinn et al. 
1978). Characterization of the tumor cell lines showed that Colo 205 is more 
aggressive than that of Colo 201 cells.  Interestingly, CC3 mRNA was also lower in 
Colo205 compared to Colo201. This suggests that CC3 may be associated with more 














































Figure 3.6 Expression profile of CC3 in colorectal cell lines 
 
(a) Relative quantification of CC3 expression by real time PCR was performed on 13 
colorectal cell lines. The names of each cell line are as indicated. Results are average 
of three independent experiments normalized to GAPDH. (b) Western Blot analysis 
was performed on 13 colorectal cell lines. The names of each cell line are indicated 
above the blots and β-actin served as loading control (top). Graph showing the 
intensities of CC3 normalised to β-actin. Results are average of three independent 





















































































































3.8 Generation of CC3 over-expressing Colo320 and HCT116 cell line 
In order to directly assess the effects of CC3, we stably transfected Colo320 and 
HCT116 cell lines, both low CC3 expressors, with CC3 plasmid or empty vector 
control. These two cell lines were also selected since Colo320 is a microsatellite 
stable cell line and HCT116, a microsatellite instable cell line. Over-expression was 















     
              
 
Figure 3.7 Over-expression of CC3 in HCT116 and Colo320 colon cancer cell 
lines.  
Over-expression of CC3 in (a) HCT116 and (b) Colo320 colon cancer cell lines was 
validated by realtime and RT-PCR (insert). Both GAPDH and Beta actin were used 
for normalization. (c) Over-expression was also validated by Western blot. Beta-actin 
served as loading control. Results shown are representative figures from at least three 
independent experiments (top). Graph showing the intensities of CC3 normalised to 
β-actin. Results are average of three independent experiments (bottom) and expressed 
as means ± SD. 
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3.9 Over-expression of CC3 inhibited cell growth 
Cell viability was measured by Trypan blue exclusion as well as Cell Titer Blue assay, 
which measures the metabolic capacity of live cells. These results demonstrate that 
Colo320 transfected with CC3 inhibits cell growth as compared to the controls in a 
time-dependent manner (Fig 3.8a and 3.8b). In cultures where serum was withdrawn, 
there was a dramatic reduction of viability in CC3 over-expressing cells after 4 days 
in culture (Fig. 3.8c). An over-expression of CC3 in HCT116 inhibited anchorage-
































































































Figure 3.8 Over-expression of CC3 in Colo320 cells is associated with reduced 
cell viability while in HCT116, reduced anchorage-independent growth.  
(a) Growth of stable transfectants and parental Colo320 cells were monitored over 5 
days by Trypan blue counting. Points are mean of three independent experiments. 
Cells were also cultured in DMEM culture media in the (b) presence or (c) absence of 
serum and monitored over 5 days by Cell Titer Blue assay. Histograms are mean of 
three independent experiments. (d) Cell anchorage independent growth was 
performed by cell growth in soft-agar. Results represent the mean ± SD of 3 































3.10 Reduction of cell growth was due to increased apoptosis 
To determine whether inhibition of cell growth was due to apoptosis, cells were 
cultured for five days, with or without serum, after which they were harvested and 
fixed. Cell cycle distribution of empty vector and CC3 transfected cells were 
analyzed by flow cytometry after staining with propidium iodide.  
 
In CC3 transfected Colo320 cells, there was a small but significant increase of sub-
G1 DNA (14.41 ± 0.49)% as compared to empty vector transfected cells (11.68 ± 
1.35) %. Upon serum withdrawal, CC3 transfected Colo320 lines had a significantly 
larger sub-G1 content of (18.86 ± 0.01) % versus (11.85 ± 2.14)% in empty vector 
cells. Representative cell cycle diagrams are shown in Fig. 3.9a and 3.9b. 
 
We further analyzed apoptosis by labeling empty and CC3 vector cells with Annexin 
V-PE, simultaneously with
 
a dye-exclusion stain, 7-amino-actinomycin D (7-AAD). 
Quantification of these data showed that CC3 over-expression triggered a reduction 
of viable cells (Annexin-/7-AAD-) from 28% to 20.5% and an increase of late 
apoptotic cells (Annexin+/7AAD+) in from 61.9% to 69.2% (Fig.3.10a and 3.10b). 
 
We utilized two qualitative tests, DNA fragmentation and TUNEL assay to further 
determine that CC3 induces apoptotic cell death. Colo320 cells transfected with 
empty or CC3 vector were harvested 5 days after plating and equal numbers were 
used for the assay. The qualitative assay, TUNEL, indicated that Colo320 transfected 
with CC3 had a higher percentage of apoptotic cells (Fig 3.11a) as compared to 
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Colo320 empty vector cells. In both serum and serum-free cultures, CC3 transfected 
cells also showed increased DNA fragmentation as compared to empty vector cells 
(Fig 3.11b).  
 
To ensure that the increased in apoptosis was not cell line specific, we analyzed the 
cell cycle profiles of both empty and CC3 transfected HCT116 cell lines (Fig. 3.12a). 
Similar to Colo320 cell lines, there was an increase of Sub-G1 DNA content in CC3 
transfected cells (6.36±0.27)% as compared to empty vector transfected cells 
(3.77±0.36)% and parental cell lines (2.40±0.31)%. Also, there was increased DNA 







Figure 3.9 Cell cycle analyses of empty vector and CC3 transfected Colo320 cell 
lines cultured in culture media (a) with FBS or (b) without FBS. Empty vector cells 
are on the left panel and CC3 vector cells on the right. Markers  M1=G0/G1 phase, 








Figure 3.10 Apoptosis of empty vector cells and CC3 vector cells were also double 
stained with Annexin-PE and 7-AAD and quantified by flow cytometry. Histogram 
shows percentage of cells in the four quadrants. Results are means of 4 independent 







































    
Figure 3.11 Analysis of apoptosis by TUNEL assay and DNA fragmentation in 
Colo320 cells.  
Both floating and adherent cells were harvested 5 days after plating. 
(a) Representative photographs of Colo320 cells transfected with empty vector (left 
panel) and CC3 transfected Colo320 (right panel). Cell nuclei were counterstained 
with DAPI. (b) For DNA fragmentation, following lysis and centrifugation at 16,000g, 
2ug of DNA was loaded into each lane. In the presence or absence of serum, CC3 
vector induced DNA fragmentation, an indication of apoptosis.  EV represents cells 
transfected with empty vector and CC3 represents cells transfected with CC3 vector. 
The leftmost lane was loaded with 100-bp DNA size markers.  
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Figure 3.12 Cell cycle analyses and DNA fragmentation of HCT116 parental and 
transfected cells. HCT116 cells were cultured in the absence of serum and harvested 
5 days after plating. 
 
(a) Cells were trypsinized and fixed overnight before staining with Propidium iodide 
and subjected to flow cytometric analyses. Markers  M1=G0/G1 phase, M2=S phase 
and M3=Sub-G1 phase. 
 (b) Following lysis and centrifugation at 16,000g, 2ug of DNA was loaded into each 
lane. CC3 vector induced enhanced DNA fragmentation, an indication of apoptosis.  
EV represents cells transfected with empty vector and CC3 represents cells 
transfected with CC3 vector. The leftmost lane was loaded with 100-bp DNA size 
markers.  
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3.11 Over-expression of CC3 reduced anti-apoptotic genes  
To further study the molecular mechanism of CC3 accompanying its apoptotic effects, 
we examined Bcl-2 family gene expression. Increased CC3 expression in Colo320 
was accompanied with a reduction of Bcl2 and Bcl-xl. However, there was no 
significant change in Bax expression. (Fig 3.13b and 3.13c).To complement this data, 
we employed a transient knockdown method by a siRNA approach (Fig. 3.13a). 
Realtime PCR results confirmed that, knockdown of CC3 was accompanied by a 
significant increase of Bcl2 and Bcl-xl, whereas there was no change in Bax 
expression (Fig 3.13b). In the mitochondrial pathway, translocation of Bax from the 
cytosol to mitochondria was required to initiate the apoptosis. Using an active 
conformation-specific Bax antibody (6A7), we did not observe any difference 
between the empty and CC3 transfected Colo320 cells (Fig 3.13d). Additional, we 
performed RT-PCR with empty and CC3 transfected SW620 (Fig. 3.13c).  Although 
there was no change in Bax, Bcl2 and Bcl-xl expression (not shown), we observed 
that in CC3-transfected SW620, there was an increase in Bak and a few BH3-only 
genes (Bad, Bim and Noxa). Caspase 3, 8 and 9 gene expression was also increased in 
CC3-transfected SW620. This increase in caspase expression is similar to a recent 
finding in gastric cell lines that over-express CC3(Li, Zhang et al. 2009). 
 
To observe whether the inverse relationship of CC3 and Bcl2 or CC3 and Bcl-xl is 
present in human tissues, we performed immunohistochemistry on both normal colon 
and gastric serial tissues sections. Normal gastro-intestinal epithelial cells are 
interesting for study as we can observe both physiological apoptosis and proliferative 
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state of the cell in a single tissue(Radtke and Clevers 2005). In normal colon and 
gastric cells, we observed that CC3 was expressed on the surface epithelium cells and 
at the top of the crypts (Fig3.14a and b). For normal gastric mucosa, staining was 
stronger on the side of the parietal/chief cells that were closer to the epithelial cells 
(Fig. 3.14b). This pattern of staining was similar to that of Bax and inverse to that of 
Bcl2 and Bcl-xl. For both the anti-apoptotic proteins, Bcl2 and Bcl-xl, staining was 
stronger at the bottom of the epithelial crypts. In parietal cells, stronger staining was 
observed on the side further away from the epithelial cells. Taken together, these 
results show that CC3 could regulate the Bcl-2 family of proteins in normal and 




         
 
Figure 3.13 Over-expression of CC3 regulates apoptosis genes.  
(a) Colo320 cells were transiently transfected with scrambled siRNA or CC3 siRNA 
at 50nM and harvested after 48hours. (b) Expression of Bax, Bcl2 and Bcl-xl by real 









































































Figure 3.13 Over-expression of CC3 regulates apoptosis genes. 
 (c) RT-PCR of Bcl2 and Bcl-xl after over-expression of CC3 in Colo320 cells. RT-
PCR of SW620 empty and CC3-transfected cells were also performed. Bak, some 
BH3 only genes and caspase genes were increased in CC3-transfected SW620 
compared to empty vector.  β-actin served as endogenous control. (d) 
Immunofluorescence of a mouse monoclonal anti-Bax (6A7) was applied to empty 
and CC3 vector cells after fixation. Anti-Bax 6A7 is directed towards a segment of 
Bax and recognizes an active form of Bax in which this segment is exposed. Anti-
mouse secondary antibody tagged to FITC was used for detection. EV represents 























   
 
   
Figure 3.14 Immunohistochemistry of CC3, Bax, Bcl-2 and Bcl-xl on normal 
colon and gastric tissue.  
The antibodies used are stated. CC3 and Bax staining appears to be similar in locality 
in both (a) colon and (b) gastric mucosa. Bcl-2 and Bcl-xl appears to be stained 
inversely, i.e.: in areas of strong CC3 staining, Bcl2 and Bcl-xl staining are weak. 
Magnification for colon samples were 20X and gastric sample were 10X. Scale 
bar=100µm 
 










3.12 Induction of apoptosis by CC3 was in part due to Bcl-2 and Bcl-xl  
To further verify that that the apoptotic mechanism of CC3 was due to Bcl2 and Bcl-
xl, double silencing was employed.   CC3 siRNA was either co-transfected with Bcl-2 
siRNA or Bcl-xl siRNA in Colo320 cells and incubated for 48hours. We achieved a 
60% knockdown effect by 50nM Bcl-2 siRNA and 50% of knockdown effect with 
50nM Bcl-xl (Fig. 3.15a). Single knockdown by Bcl-2 or Bcl-xl did not affect CC3 
expression (not shown). Since over-expression of CC3 reduced cell viability, we 
would expect to see an increase in growth in cells where CC3 was knocked down. We 
used CyQuant assay, which measured the DNA content of cells in a 96-well plate 
format. There was an increase in growth in CC3 silenced cells as compared to 
scrambled control (Fig. 3.15b). In double-transfected cells, this increase in 
proliferation was reduced. This suggests that the induction of cell growth by CC3 was 
in part, due to Bcl2 and Bcl-xl. As expected, cell transfected with Bcl2 or Bcl-xl 







Figure 3.15 Co-transfection of CC3 and Bcl2 or CC3 and Bcl-xl abolished the 
increase in proliferation due to CC3 silencing.  
(a) Silencing of Bcl2 and Bcl-xl was confirmed by realtime PCR. (b) Co-transfections are 



















































































































3.13 CC3 is up-regulated in colorectal cell lines upon 5-FU treatment 
5-fluorouracil (5-FU) is the most commonly used drug for colorectal cancer treatment, 
yet its efficacy is not uniformly effective. One reason is due to acquired resistance in the 
tumor. The ability to identify markers that could predict response is therefore important 
and may provide insights to the different 5-FU sensitivities among tumors.   As shown by 
Zhao et al, they found that CC3 over-expressing hepatocellular carcinoma (HCC) cells 
lines when combined with 5-FU treatment, developed smaller tumors compared to 
control cells(Zhao, Zhang et al. 2006). In addition, mice in this treatment group survived 
longer than mice injected with CC3-overexpressing HCC-only or control cells treated 
with 5-FU only. This implies that CC3 sensitizes the cells to 5-FU-induced death. Hence, 
we investigated how CC3 may have synergistic effects with 5-FU in colorectal cancer.     
 
First, we estimated the IC50 of four colorectal cell lines (Colo320, HCT116, SW480 and 
SW620) after 72 hours of treatment with 5-FU. IC50 is estimated by the concentration 
which reduced 50% of the cell viability, measured by CellTiter Blue assay. Based on the 
IC50 values, we also treated the cell lines and harvested them in a time dependent manner. 
IC50 of Colo320 and HCT116 was approximately 5µM 5-FU respectively (Fig 3.16a). 
IC50 values of SW480 and SW620 were 20µM and 50µM respectively(Fig 3.16b). Since 
SW480 and SW620 were derived from the same patient, we treated both cell lines with 
20µM of 5-FU, to elucidate possible differences in their drug resistance. 
 
Results for Colo320, HCT116 and SW480 were similar, even though Colo320 and 
HCT116 cells harbored a wild type p53 and SW480 cells were of p53 mutant type. This 
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suggests that induction of apoptosis by 5-FU may or may not be p53 dependent. The 
sensitivity of tumor cells to 5-FU had been shown to be unrelated to p53 status and 
functionality but rather, Bcl-2/Bax ratio appeared to be a more relevant marker (Mirjolet, 
Barberi-Heyob et al. 2000). In these 3 cell lines, cell viability reduced in a time 
dependent manner, whereas in SW620, there was a slight increase in cell numbers at later 
time points. Concomitantly, in Colo320, HCT116 and SW480, there was an induction of 
CC3, at mRNA and protein levels (Fig3.16 c and d). For Colo320 cell line, CC3 protein 
was undetectable.  In contrast, SW620 (a highly resistant cell line to chemotherapeutic 
drug treatment), had little change and a slight decrease in CC3 expression a later time 
points, at both mRNA and protein levels. This suggests that the increase of CC3 
expression may sensitize cells to drug-induced cell death.    
 
There have been many reports which indicate that Bcl-2 family play key roles in drug-
induced cytochrome c release(Cory, Huang et al. 2003), hence, we investigated gene and 
protein expressions in the mitochondrial pathway upon 5-FU treatment. In RT-PCR 
analyses, there was a time-dependent increase in Bax and caspase 3 gene expressions in 
both HCT116 and SW480 cells lines but not SW620 (Fig 3.16c).  Bcl-2 and Bcl-xl gene 
expressions reduced at 24-hr and 72-hr respectively in all the 3cell lines.  
 
Time course analyses of protein expressions revealed that pro-apoptotic Bax expression 
in HCT116 and SW480 was reduced at about 72-hr (Fig 3.16d). In contrast, the reduction 
of Bax reduced at an earlier time point (24-hr) in SW620. Bcl-2 and Bcl-xl expression 
kinetics were similar in the 3 cell lines. Cytochrome c in both HCT116 and SW480 was 
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increased at an earlier time-point (8-hr for HCT116 and 4-hr for SW480). However, in 
SW620, this release was much delayed at 24-hr time-point. In addition, both Smac 
(second mitochondria-derived activator of caspase) and AIF (apoptosis-inducing factor) 
were also increased in both HCT116 and SW480. However, protein levels of both Smac 
and AIF remained relatively the same even up to 96-hr of treatment. In addition, the 
cleavage of caspase 9 and caspase 3 occurred at much earlier time-points in HCT116 and 
SW480 than SW620. In HCT116 and SW480, cleavage occurred at 12-hr and 8-hr 
respectively, while in SW620, cleavage occurred at about 24-hr. PARP, a substrate of 
caspase 3, was also cleaved at earlier time points in HCT116 and SW480 compared to 
SW620. All these suggest that the differential kinetics in regulation of CC3 and other 
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Figure 3.16 Time-course treatment with 5-FU in colorectal cell lines. 
(a) Viability of Colo320 and HCT116 cell lines after 5µM of 5-FU treatment. (b) 
Viability of SW480 and SW620 cell lines after 20µM of 5-FU treatment. SW620 is 
highly resistant to many chemotherapeutic drugs. (c) Gene expression analyses of CC3 
and Bcl-2 family upon 5-FU treatment. (d) Protein analyses of CC3 and apoptotic 




3.14 Over-expression of CC3 sensitized cells to drug-induced cell death  
Control and CC3 expressing Colo320 were exposed to 5-Fluorouracil for 72hours. 5-FU 
induced a significant decrease in viability in CC3 expressing cells as compared to the 
control in a dose-dependent manner (Fig. 3.17a). When both empty and CC3 vector 
Colo320 and HCT116 cells were treated at a high dose of 100µM 5-FU, CC3 expressing 
cells had increased DNA fragmentation as compared to their respective empty vector and 
parental cells (Fig. 3.17b). 
HCT116 SW480 SW620 




































In cell cycle analyses, 5-FU induced S-phase arrests as evidenced by a larger fraction of 
cells in the G1 phase, in both empty and CC3 vector cells as compared to cells which 
were untreated. At low doses of 5-FU treatment, CC3 induced increase in Sub-G1 phase 
and a reduction in S phase compared to empty vector in both cell lines, although the 
increase in Sub-G1 phase was not significant in CC3-transfected HCT116 (Fig.3.17c and 
Table 3.4). At high doses of 5-FU treatment, a similar pattern was observed, where CC3 
induced an even larger increase in Sub-G1 phase and an S phase arrest. However, the S 
phase reduction was not significant between CC3-transfected HCT116 and its empty 
















































Figure 3.17 CC3 sensitizes Colo320 and HCT116 cells to drug-induced cell death 
(a) Colo320 empty and CC3 vector cells were treated with 5-Fluorouracil (5-FU) for 
72hours at indicated doses. 
 
 (b) Colo320 and HCT116 cell lines and its derivatives were treated with 100uM 5-FU. 
After 72hours of treatment, cells were harvested and 2µg of DNA was loaded into each 
lane. CC3 vector induced increased DNA fragmentation as compared to empty vector 
control.  EV represents cells transfected with empty vector and CC3 represents cells 
transfected with CC3 vector. The leftmost lane was loaded with 100-bp DNA size 
markers.  
 
(c) Effect of low and high doses of 5-FU treatment on empty and CC3 transfected cell 
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Table 3.4 Cell cycle analyses of CC3 over-expression in Colo320 and HCT116 cells after 
low and high doses of 5-FU drug treatment 
  Colo320 HCT116 
Low dose 5-FU Sub-G1 (%) S phase (%) Sub-G1 (%) S phase (%) 
Empty Vector 32.88.±1.15 16.03±0.54 35.13±0.77 18.53±1.08 
CC3 Vector 37.16±0.28 13.19±0.511 40.67±2.11 15.55±1.15 
p value * ** NS * 
     
 
Colo320 HCT116 
High dose 5-FU Sub-G1(%) S phase (%) Sub-G1(%) S phase (%) 
Empty Vector 69.67±2.32 5.38±0.78 57.78±0.78 6.30±0.04 
CC3 Vector 77.66±0.66 3.94±0.21 65.40±2.31 4.92±0.57 
p value ** * * NS 
 
 
3.15 Caspase activity was sustained for a longer time course in CC3-transfected 
Colo320 
To determine whether this decreased viability after 5-FU treatment in CC3 transfected 
cells was caspase-dependent, we subjected the cells to 10uM of 5-FU and analyzed the 
caspase 3/7-activities in a time-dependent manner. While the caspase-activity of 5-FU 
treated empty vector cells reduced after 24hours, CC3 vector cells sustained the caspase 
activity up to 96hours after 5-FU treatment (Fig 3.18a). To further validate that this was 
indeed due to caspases, we pre-treated the cells with broad spectrum caspase inhibitor, z-
VAD-fmk, for an hour before subjecting the cells to 5-FU treatment for 48 and 72hours. 
These time points were chosen since empty vector cells treated with 5-FU had 
significantly lower caspase3/7 activities as compared to CC3 vector cells. Pre-treatment 
with caspase inhibitor abolished this increase in caspase activity (Fig 3.18b). PARP is 
substrate of active caspase3. We observed that in CC3 transfected cells, PARP was 
cleaved at earlier time point (4-h) and this was sustained until 96-h time-point, where 
109 
 
almost all the substrate was cleaved. In contrast, in empty vector cells, PARP was 
cleaved at 8-h and was cleaved in smaller amounts at later time points compared to CC3 
vector (Fig.3.18c). In addition, we observed an increase of CC3 expression in a time-
dependent manner, both in empty and CC3 vector cells (Fig.3.18c top panel). 
This suggests that the presence of CC3 sustained caspase activity in cells upon 5-FU 
treatment. Colo320 empty and CC3 vector cells were also subjected to 5µM Etoposide, 














































































































































Figure 3.18 Caspase activities in 5-FU treated Colo320 empty and CC3-transfected 
cells 
(a) Colo320 empty and CC3 vector cells were treated with 10µM of 5-FU at the 
indicated time points and caspase activity was measured as a ratio of the DMSO 
control.  
(b)  Empty and CC3 transfected cells were treated with10µM of 5-FU for 48 and 
72hours. Cells pre-incubated with pan-caspase inhibitor (z-VAD-fmk) are as 
indicated. The results are average of at least 2 independent experiments. ***p<0.001, 
* p<0.05.  
(c) Colo320 empty and CC3 vector cells were treated with 10µM 5-FU and harvested at 
similar time points as (a). PARP, a substrate of caspase3, was cleaved at 4-hour time 
point for CC3-transfected cells as compared to empty vector. At 96-hour, in CC3 
vector cells, almost all the substrate was cleaved. Graphs shown below western blots 
are average of at least 2 independent experiments. **p<0.005, * p<0.05 compared to 
zero time point control.  
 
 
3.16 Sustained caspase activity in CC3 vector cells is, in part due, to increased active 
Bax  
To further investigate possible differences in caspase activity upon 5-FU treatment, 
signaling mediators upstream of caspases were considered. In particular, we looked at Bcl 
family of proteins since they are important players in the mitochondrial pathway. It was 



























































CC3 expressing cells while Bax expression was only increased at 24-hour time-point (Fig. 
3.19a). More importantly, using an antibody which recognizes only active Bax by 
immunofluorescence, we observed that active Bax was consistently present in CC3 
transfected cells after 5-FU treatment and not present in empty vector cells (Fig. 3.19b). 
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Figure 3.19 CC3 vector cells induced active Bax at earlier time points upon 5-FU 
treatment  
(a) Western blot analyses of 5-FU treated empty and CC3 vector cells at indicated 
time points (top). CC3 expressing cells induced Bax expression at 4-h time-point 
while empty vector cells induced Bax at 24-h, upon 5-FU treatment. Graphs presented 
are average of at least 3 independent experiments.  * p<0.05. 
Immunofluorescence of active Bax in (b) empty vector (top panel) and (c) CC3 vector 
cells (bottom panel). Active Bax was consistently present in CC3 expressing cells to 












3.17 Hypermethylation of CC3 promoter is associated with transcriptional 
repression 
Next, we sought to define the mechanism by which CC3 may be down-regulated in 
colorectal cancer. Recently, it has been shown that the epigenetic inactivation of tumor 
suppressor genes by the hypermethylation of their promoter regions is frequently 
observed in human cancers(Jones and Baylin 2002). We hypothesized that this may be 
the case for CC3. First, we used a promoter prediction software to examine the genomic 
sequence encompassing the SDF1 gene, including 1kb of sequence upstream of the 5'-
UTR. Using CpG analysis software we determined that this region of the promoter was 
G/C rich, extending from -264 to +630 (Fig. 3.20a). In this region, 3 CpG islands were 
identified: one located in the 5’-UTR of CC3, one in exon 1 and the third at intron1. This 
region is similar to a recently published report where the authors found that methylation 
of CC3 promoter was associated with higher recurrence rate, mortality and lower disease-
free interval in patients with hepatocellular carcinoma(Tong, Li et al. 2009) 
 
We analyzed the first region, which encompasses 26CpG islands, by bisulfite sequencing. 
Two colorectal cell lines, Colo320 and SW403, were chosen for analyses since Colo320 
was a low CC3 expressor and SW403 expressing high levels of CC3 mRNA (Fig 3.6a). 
DNA from the two cell lines were first bisulfite treated. The region encompassing 26 
CpG islands was then amplified and cloned by TA cloning. After bacterial transformation, 
10-12 clones were randomly selected and sequenced.  As shown in figure 3.20b, 
methylation of the CC3 promoter was readily detectable in Colo320 while in SW403, 
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most of the clones were not methylated in this region. This suggests that methylation may 




Figure 3.20 CC3 promoter is methylated in Colo320 cell lines 
(a)The 5’ region of CC3 gene contains a large CpG island (blue area), which includes a 
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                           Figure 3.20 CC3 promoter is methylated in Colo320 cell lines 
 (b) Methylation map of 26 CpG islands. Horizontal axis show methylation status of CpG 








3.18 Inhibition of DNMT enzymes restored CC3 expression in Colo320 
To better define mechanism which may lead to CC3 promoter hypermethylation, we first 
determined DNMT (DNA methyltransferase) expression in 13 colorectal cell lines by 
realtime PCR. The methylation status of mammalian genome is tightly regulated by 
DNMT family(Bestor 2000). Interestingly, cell lines which had low CC3 expression 
(Colo320 and HCT116), had high mRNA expression of DNMT1 and DNMT3b. SW620, 
a cell line derived from the lymph also had much higher levels of DNMT3b as compared 
to SW480, a cell line derived from the primary tumor of the same patient (Fig 3.21). This 
inverse relationship suggests that low expressors of CC3 may be hypermethylated in their 
promoters due to increased levels of DNMT enzymes. 
 
Next, we sought to determine if inhibition of DNMT could re-establish CC3 expression. 
Treatment of Colo320 with 5-Aza-dC restored CC3 mRNA expression in a dose-
dependent manner (Fig 3.22a and b). 5-Aza-dC is a drug which incorporates into DNA to 
cause an irreversible inactivation of DNMT. Viability of cells was reduced with 
increasing dose and days of 5-aza-dC treatment (Fig. 3.22c). At the same time, we show 
that DNMT1 and DNMT3b expression was indeed reduced when cells were treated with 
5-aza-dC(Schneider-Stock, Diab-Assef et al. 2005) (Fig 3.22d). 
 
CC3 expression is inducible by cytotoxic drugs. To ensure that re-expression of CC3 was 
specifically due to de-methylation of CC3 promoter and not other non-specific cytotoxic 
effects (for example, due to induction of interferon pathway)(Schmelz, Sattler et al. 
2005) , we analyzed DNA from 5-aza-dC treated cells by bisulfite sequencing (BSP) and 
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methylation specific PCR (MSP). Both BSP (Fig 3.22e) and MSP (Fig 3.22f) showed that 
5-aza-dC treatment inhibited the methylation of CC3 promoter. Even though methylation 
was not completely inhibited (ie hemi-methylated), CC3 expression was partially restored.  
Taken together, these data indicate that pharmacological DNMT inhibition prevents 




Figure 3.21 DNMT1 and DNMT3b expression in 13 colorectal cell lines 
Real time PCR results show varying DNMT expression in cell lines. Interestingly, 2 cell 
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Figure 3.22 Gene re-expression and DNA demethylation after 5-Aza-dC treatment 
in Colo320 cell lines. 
(a)Real time PCR and (b) RT-PCR results show a significant re-expression of CC3 gene 
upon 5-Aza-dC treatment for 72hrs. (c) Viability of Colo320 cells with varying doses and 
period of incubation with 5-Aza-dC. (d) Realtime PCR shows that 5-Aza-dC treatment 
reduces DNMT1 and DNMT3b. (e) BSP and (f) MSP for CC3 promoter show that upon 
5-Aza-dC treatment, the promoter of CC3 is partially demethylated compared to DMSO 
control. In (e), horizontal axis show methylation status of CpG island (numbered 1 to 26). 























3.19 Hypermethylation of CC3 promoter contributes to survival of Colo320 
Next, we were interested to see if hypermethylation of CC3 promoter attenuated its pro-
apoptotic activity upon 5-FU treatment. We exposed the cells to 5-Aza-dC for 72hours 
and a further treatment of 10uM 5-FU for 48hours sequentially. Inhibition of methylation 
sensitized the cells to chemotherapeutic drugs and causes a reduction in the viability of 
cells. Since 5-Aza-dC reverses the methylation of all promoters and causes re-expression 
of many tumor suppressor genes (including CC3), this reduction of viability might be due 
to other tumor suppressors. To address this, we also silenced CC3 together with 5-Aza-
dC treatment, to observe if cells had increased viability. Upon 5-Aza-dC and 5-FU 
treatment alone, there was a re-expression of CC3 accompanied with lower viability.  
 
However, the addition of CC3 siRNA, specifically reduced CC3 expression and increased 
cell viability (Fig. 3.23a). In addition, we observed that Bcl-xl expression was reduced 
upon 5-Aza-dC+5-FU treatment (Fig. 3.23b). However, it is possible that this reduction 
of Bcl-xl may be due to other tumor suppressors. Upon the addition of CC3 siRNA, Bcl-
xl expression was increased again (Fig. 3.23b). This is in agreement with our findings in 
the previous section, where CC3 and Bcl-xl share an inverse relationship. In summary, 
hypermethylation of CC3 promoter could be reversed by 5-Aza-dC to re-express CC3 
gene. The re-expression of CC3 could sensitize cancer cells to chemotherapeutic drugs, 




           
           
Figure 3.23 Treatment of Colo320 by 5-Aza-dC restores CC3 expression 
(a) Sequential treatment of cells by 5-Aza-dC and 5-FU re-expressed CC3 and caused a 
reduction in viability. The addition of CC3 siRNA abolished this increase in CC3 and 
more cells survived. 
(b) Sequential treatment of cells by 5-Aza-dC and 5-FU caused a reduction in Bcl-xl. 
Upon addition of CC3siRNA, Bcl-xl expression was increased. 








































































































3.20 Over-expression of CC3 in HCT116 cell line suppressed cell invasion through 
extracellular matrix (ECM) 
Since CC3 expression was found to be reduced in metastasized colon cancer, we 
hypothesized that CC3 may also affect cell invasion. We next analyzed the ability of CC3 
transfected cells to invade the basement membrane by Matrigel invasion assay. HCT116 
CC3 vectors cells exhibited reduced invasive ability (~42% of control cells) through 
Matrigel-coated inserts as compared to empty vector control cells (Fig 3.24a and b). To 
distinguish between the invasion and motility, the rate of wound closure was used to 
measure cell motility
 
in wound healing assays. It was observed that there was no apparent 
difference in wound healing between empty and CC3 vector cells, even up to 5 days (Fig 
3.25). This suggests that inhibition of invasion through Matrigel by CC3 is independent 
of motility. In addition, over-expression of CC3 was accompanied with a reduction of 
matrix metalloproteinase-1 (MMP1) (Fig 3.24c), consistent with a recent finding(Zhao, 
Lu et al. 2008).  These data support the hypothesis that CC3 reduces invasive ability, in 












Figure 3.24 CC3 suppressed HCT116 cell invasion through ECM  
(a) and (b) CC3-transfected HCT116 had significantly reduced invasion as compared to 
empty vector-transfected HCT116 as well as the parental lines.   Results represent the 
mean ± SD of 3 experiments; each conducted in triplicates  
(c) Over-expression of CC3 reduced MMP1 mRNA levels. RT-PCR of MMP1  











































Figure 3.25 Wound healing assay of Empty and CC3 transfected HCT116 
 
Motility was examined in wound healing assays over 5 days as described under 
"Materials and methods" section 2.6.10. There was no obvious difference in the rate of 















As an initial step to assess the role of CC3 in colorectal cancer progression, we 
determined its tissue distribution in normal and neoplastic colorectal tissues. In this 
dissertation, we first describe the generation of a human monoclonal antibody that reacts 
specifically with the CC3 protein and works well for immunohistochemical detection in 
sections of formalin-fixed paraffin-embedded tissue. Using this technique, we have 
described the in vivo distribution of CC3 in normal and neoplastic colorectal tissues, for 
the first time. In addition, we extended our study to include various other tumor types. 
 
In this study, we found that CC3 expression was exclusive to epithelium lining the 
surface and the top of the crypts, while staining negatively at the base of the crypts, in 
normal colorectal tissues. This observation is consistent with an in vitro system, which 
mimics normal intestines(Lindfors, Halttunen et al. 2001). Previous studies of zonal 
distribution of mitoses in normal colonic mucosa showed that mitotic figures were mainly 
located at the base of the crypts(Wong, Mandir et al. 2002). Furthermore, cells at the base 
of the crypts were always stained positive for Ki67, a proliferative marker(Radtke and 
Clevers 2005). Taken together, cells residing at the base of crypts are proliferative. Based 
on the physiology of normal colonic mucosa, cells at the surface epithelium are 
committed to cell death. We also stained normal colon tissues with Bax, a pro-apoptotic 
protein. Interestingly, Bax resided at the same location as CC3 (Fig 3.14a). Consistent 
with the patterns of epithelial cell self-renewal and death in the colon, CC3 staining 
tended to be greater in the colonic epithelial cells that had migrated up the crypts towards 
the luminal surface and that are destined for programmed cell death than in the long-lived 
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rapidly proliferating cells located in the bases of the crypts. This similarity in 
immunostaining may suggest a putative role for CC3 in epithelial differentiation and 
morphogenesis, as been suggested for Bcl-2 family(Lu, Abel et al. 1996). In another 
gastrointestinal (GI) study(Li, Zhang et al. 2009), CC3 expression in normal gastric 
mucosa was reported to be positive without further description in of its locality. Our 
study hence provides more details to the localization of CC3 (Fig 3.14b). The unique 
topology of normal colon also suggests for the inclusion of immunostaining to be 
performed together with immunoblotting, in order to understand colorectal cancer 
tumorigenesis.  It would be interesting to investigate if normal tissues in the GI tract are 
differentially stained for CC3.    
 
Several protein and genetic markers have been described in an attempt to refine 
prognostic information. Even though none of these markers is in routine clinical use, 
progress has been made in other tumor types towards such goals. For example, in breast 
cancer, hormone receptor status is associated with prognosis. Identification of molecular 
markers which provide insight into the potential behavior or aggressiveness of tumors is 
an essential step for the improvement of cancer treatment. The limited value of a single 
molecular marker is not surprising because tumors frequently express multiple proto-
oncogenes and suppressor genes, each of which may contribute to tumor progression and 
metastasis. Thus, a better understanding of tumor behavior or aggressiveness may be 




We have also correlated the expression of CC3 with the staging of colorectal cancer 
(Table 3.2).  CC3 expression was found to be significantly reduced in advanced cancers 
(Stage III and IV) and cancers which metastasized to the liver (Fig 3.4). mRNA from 
laser captured microdissected (LCM) cells also revealed that Stage IV cells had lower 
expressions of CC3 than stage II cells. By employing LCM, we can accurately evaluate 
gene expression specifically in cancer cells independent of surrounding stromal 
tissue(Makino, Uetake et al. 2008). These findings are supported by CC3 
immunohistochemical studies in other organs(Zhao, Ni et al. 2007; Li, Zhang et al. 2009; 
Tong, Li et al. 2009) where reduced CC3 expression was correlated with tumors of worse 
prognostic histopathology.  In addition, all colorectal cancer cases of mucinous subtypes 
stained negatively for CC3, while other subtypes have a varying degree of staining (Table 
3.1). Previous reports have suggested that mucinous colorectal adenocarcinomas are more 
advanced at diagnosis and have a poorer prognosis than non-mucinous colorectal 
adenocarcinomas(Kanemitsu, Kato et al. 2003). Taken together, these findings suggest 
that CC3 may be potentially useful as a prognostic marker, where negative or weak 
staining in CC3 may be indicative of more aggressive behavior. In agreement with many 
tumor suppressors, like p21(Mitomi, Mori et al. 2005), nuclear accumulation of 
p53(Manne, Myers et al. 1997) and  β-catenin(Hugh, Dillon et al. 1999), differential 
expression patterns are associated with clinical outcome of patients and has prognostic 
significance.  
 
In another TMA experiment, loss of CC3 in precancerous polyps suggested that its down-
regulation may occur as a relatively early event in the progression of colorectal cancer 
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(Table 3.1). A loss of CC3 expression may be one of the early events of neoplastic 
transformation to help abnormal cells survive by escaping from the regulatory 
mechanism of programmed cell death. This hypothesis in precancerous lesions is not new, 
as pre-malignant lesions of  gastrointestinal glands stain positively for Bcl-2(Nakamura, 
Nomura et al. 1997) and Bcl-xl(Krajewska, Moss et al. 1996), both of which are anti-
apoptotic proteins. Being implicated in the apoptotic pathway, CC3 may play a role 
similar to the Bcl-2 family. However, we would need to increase the number of cases to 
support this pilot study.  
 
Although the main focus of this dissertation is to examine the role of CC3 in colorectal 
cancer, the increasing recognition in CC3 as a tumor suppressor led us to explore its 
expression in other cancers and to examine the sometimes paradoxical results from other 
groups. 
 
In general, we observed positive CC3 staining in all normal tissues but with varying 
intensities. This observation is in line with a previous finding by northern blot where CC3 
was found to be ubiquitously expressed in all tissues(Shtivelman 1997). The widespread 
expression of CC3 suggests a role for this protein in the regulation of cell survival and 
death in various types of cells. In spite of its ubiquitous presence in normal tissues, mice 
deficient for CC3 have no apparent developmental abnormalities(Ito, Jiang et al. 2003), 




In tumor tissues, our results are in agreement with studies done by other groups. In 
lung(Tong, Li et al. 2009) and liver(Ito, Jiang et al. 2003) cancers, a down-regulation of 
CC3 was observed, suggestive of its role as a tumor suppressor. The increase in CC3 
expression in prostate cancer as compared to the normal was also supported by a recent 
study where the authors found higher CC3 expression in more aggressive prostate cancer 
and its over-expression reduced invasiveness of prostate cell lines(Zhang, Zhang et al. 
2008).  In kidneys and testis, CC3 was significantly down-regulated in the carcinoma 
compared to the normal. While in brain, skin, thyroid and pancreas CC3 was significantly 
up-regulated in carcinomas. Each of these cancer groups should be further investigated 
independently to further elucidate possible functions of CC3. It is tempting to speculate 
that CC3 has bi-functional roles as tumor suppressor and oncogene similar to reports in 
TGFβ, which also has dual roles. However, more work has to be carried out to explain 
this apparent dichotomy of CC3. 
 
Previous reports suggest that the tumor suppressive effects of CC3 may be due to its pro-
apoptotic functions. However, molecules in the Bcl-2 family are not similarly regulated 
in different cancer types. For example, in testicular tissues, elevated expression of Mcl-
1(anti-apoptotic) was found in seminoma and low expression was detected in normal 
testicular germ cells, in line with its expectation as an oncogene. 
 
However, bid expression (a pro-apoptotic protein) was found to be higher in gliomas and 
advanced prostate cancers (T3) compared to earlier stage (T1 and T2)(Krajewska, Zapata 
et al. 2002). Similarly, contrary to a priori expectations of pro-apoptotic function of Bax, 
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the immunointensity of Bax was often higher in more advanced tumors compared with 
earlier stage neoplasms. Bax immunointensity was typically higher in gliomas (WHO 
grade IV) and astrocytomas (WHO grade III) compared with astrocytomas (WHO grades 
I and II)(Krajewski, Krajewska et al. 1997). In skin cancers, advanced stage and 
metastatic melanomas, immunostaining of anti-apoptotic Bcl-2 was diminished compared 
to normal melanocytes(Tron, Krajewski et al. 1995). In thyroid tissues, papillary thyroid 
carcinomas had lower Bcl-2 immunostaining intensities than normal tissues(Mitselou, 
Peschos et al. 2004). It has been suggested that Bax may be anti-apoptotic(Middleton, 
Nunez et al. 1996) and Bcl-2 being pro-apoptotic in a cell dependent context(Pietenpol, 
Papadopoulos et al. 1994; Borner 1996; Mazel, Burtrum et al. 1996), hence it is possible 
that CC3 may exert different apoptotic properties in different cell types. In addition, high 
levels of Bax in advanced tumors may be offset by elevations in the levels of anti-
apoptotic proteins such as Bcl-2, Bcl-xl, and Mcl-l, thus explaining the apparent 
discrepancy between higher levels of Bax and tumor progression(Krajewski, Krajewska 
et al. 1997).  These suggest that a complex network of apoptotic proteins is involved in 
tumorigenesis in these tissues and it would be beneficial to consider a panel of pro-
apoptotic and anti-apoptotic proteins, including CC3, in the regulation of tumor 
progression.  
 
Nonetheless, based on the immunostaining results we obtained, we hypothesized that 
CC3 acts as a tumor suppressor in colorectal cancer tissues. We found no mutations in 
exon3 of CC3 in colorectal cancer tissues cell lines, similar to findings in breast 
cancers(Zhang, Wong et al. 2005; Zhao, Ni et al. 2007). Hence we focused on the 
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modulation of CC3 in colorectal cell lines.  In order to further investigate the possible 
functions of CC3 in human colon cancer cells, we studied the effects of CC3 over-
expression in colorectal cell lines. 
 
Over-expression of CC3 inhibited cell growth as shown by proliferation and 
clonogenicity assays (Fig 3.8). As growth is a balance of cell survival and death, we 
decided to explore if the reduction in growth was due to increased cell death since 
immunostaining patterns in colorectal tissues suggest that CC3 may be associated with 
apoptosis. Furthermore, in liver and lung cancer studies, CC3 was found to exert its 
tumor suppressive functions through apoptotic pathways(Shtivelman 1997; Xiao, Palhan 
et al. 2000).  Indeed, over-expression of CC3 increased percentages of apoptotic cells as 
revealed by cell cycle, Annexin-V/7AAD, TUNEL and DNA laddering assays (Fig 3.9, 
3.10, 3.11 and 3.12).   
Biochemical studies have suggested that some proteins do not induce apoptosis per se but 
maintain appropriate balance of pro- and anti-apoptotic genes in order to establish the 
sensitivity of cells to apoptosis(Vaux and Korsmeyer 1999).  In this regard, we 
specifically investigated a number of apoptotic genes. CC3 induced a down-regulation of 
Bcl-2 and Bcl-xl, both anti-apoptotic genes. This finding is similar to hepatocellular 
carcinoma (HCC) and variant small cell lung cancer (v-SCLC) cell lines transfected with 
CC3. In another colorectal cell line, SW620, over-expression of CC3 induced other pro-
apoptotic genes like Bad, Bak and caspases -3,-8 and -9 (Fig 3.13c). This is consistent 
with findings in gastric cancer cell lines, where they similarly found increased expression 
of caspase genes(Li, Zhang et al. 2009). Even though the types of gene expression differ 
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in colorectal cancer cell lines of difference lineage, these genes are common in the 
mitochondrial pathway, suggesting death inducing capability of CC3 converge at these 
common effectors. These findings suggest that CC3 may exert its biological activities 
through mitochondrial pathways. 
 
5-FU been the most widely used drug for colorectal cancer adjuvant chemotherapy for 
four decades. It has been previously demonstrated that the mitochondrial pathway of 
apoptosis exerts a key role in drug-induced apoptosis(von Haefen, Wieder et al. 2003). 
Disruption of mitochondrial apoptosis signaling and concomitant development of 
anticancer drug-resistance occurs, for instance, in the over-expression of anti-apoptotic 
proteins or loss of pro-apoptotic proteins. While others have reported on possible 
apoptotic pathway that CC3 may be involved in other cancers, they have not delineated 
how CC3 respond upon 5-FU treatment. In the present study, we address the role of CC3 
in the sensitization of 5-FU.  
Consistent with this hypothesis, it has been demonstrated that variant small cell lung 
cancer (v-SCLC) cell lines transfected with CC3 were more sensitive to death inducing 
signals such as serum deprivation and chemotherapeutic drugs. In hepatocellular 
carcinoma (HCC), CC3 inhibited growth of HCC xenografts and increased survival of 
mice(Zhao, Zhang et al. 2006).  
 
Our findings that proliferation is inhibited by CC3, is consistent with the observations 
that CC3 is up-regulated upon 5-FU drug treatment (Fig 3.16 c and d). In this study, 5-FU 
induced cytochrome c release and subsequent activation of the initiator caspase 9 and 
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downstream effector, caspase 3, indicating activation of the mitochondrial pathway. This 
finding is in agreement with other studies published(Li, Nijhawan et al. 1997; Martinou, 
Desagher et al. 2000). We show that in the progression of a colorectal carcinoma a 
primary tumor (SW480) to a lymph node metastasis (SW620), the tumor cells acquired a 
5-FU-resistant phenotype.  It is worthy to note that CC3 RNA expression was found to be 
lower in SW620 than in SW480, as described by Hewitt(Hewitt, Brown et al. 2000) and 
our data (Fig 3.6). This may imply that inherent loss of CC3 may have contribution to its 
5-FU resistance, although this observation is highly speculative. The resistance in SW620 
compared to SW480 in many drugs has been shown in other studies as well(Tevaearai, 
Laurent et al. 1992; Arita, Kambe et al. 1997; Ndozangue-Touriguine, Sebbagh et al. 
2008).  
 
The inhibition of cell death upon 5-FU treatment was likely to be due to a delayed 
activation of caspase-3 in SW620 (Fig 3.16d). It is conceivable that this delayed 
activation is due to delayed activation of caspase-9 and release of cytochrome c, both 
upstream of caspase-3. Furthermore, in SW620, cytosolic Smac expression remained the 
same throughout the time course treatment of 5-FU. All these may lead to the increased 
resistance of SW620 to 5-FU treatment. 
 
The mitochondrial death pathway
 
is initiated by cellular signals that ultimately effect
 
the 
mitochondria, leading to the release of cytochrome c and
 
caspase activation(Green and 
Kroemer 2004). Our finding that caspase-9 is activated
 
downstream of CC3 implicates
 
a 
mitochondrial death pathway in CC3-induced apoptosis. The
 
lack of caspase-8 activation 
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further supports the notion that a mitochondrial
 
rather than a death receptor (extrinsic) 
pathway is involved. 
It was also intriguing to observe that only in SW620, CC3 expression was down-
regulated in a time-dependent manner but upregulated in HCT116 and SW480, both 5-
FU sensitive cell lines. The pro-apoptotic role of CC3 makes it an extremely attractive 
marker in predicting 5-FU sensitivity.  
  
Concomitantly, while CC3 was downregulated in SW620, the downregulation of Bax 
occurred at an earlier time-point in SW620, compared to SW480 and HCT116, upon 5-
FU treatment (Fig 3.16d). We decided to explore the possibility of CC3 and Bax-
dependent apoptosis in sensitizing the cells to cell death. As reported by Johnstone et 
al(Johnstone, Ruefli et al. 2002), sensitivity to chemotherapeutic drugs is regulated by 
interactions between the drug and its targets (drug-target interaction). Depending on the 
dose of treatment, drug-induced damage either result in catastrophic death or it initiates a 
series of secondary effects that leads to apoptosis. We utilized our CC3 stably-transfected 
Colo320 cell line with its empty vector control to study if 5-FU works synergistically 
with CC3.  
Upon 5-FU treatment, cell growth was inhibited by caspase inhibitors indicating again, 
that activation of caspases is one critical event in CC3-induced cell death (Fig 3.18b). In 
addition, we show that PARP, a substrate of caspase-3, was cleaved at earlier time points 
in CC3 transfected cell lines (Fig 3.18c). While an over-expression of CC3 alone was not 
enough to up-regulate or activate Bax (Fig 3.13d), 5-FU treatment and the presence of 
CC3 activated Bax (Fig 3.19c). It is well accepted, in general, that the small portion of 
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initially activated Bax plays a role in positive feedback regulation of Bax activation. For 
example, the anti-apoptotic Bcl-2 or Bcl-xl protein only interacts with conformationally 
changed Bax(Hsu, Wolter et al. 1997); over-expression of Bcl-2 blocks Bax 
conformational change and mitochondrial translocation in response to apoptotic 
signals(Murphy, Streips et al. 2000). Hence, even though CC3 could regulate Bcl-2 and 
Bcl-xl, only the synergistic effect of CC3 and 5-FU treatment caused the activation of 
Bax, eventually leading to significantly increased apoptosis (Fig 3.17).  The search for 
predictive markers for 5-FU has been a difficult process given that some studies have 
demonstrated significant efficacy for markers like p53(Ahnen, Feigl et al. 1998; Elsaleh, 
Powell et al. 2001) others have contradicted such findings(Berglund, Edler et al. 2002; 
Allegra, Paik et al. 2003). The concept that multiple markers can improve prediction of 5-
FU response urges for the search of more markers and in our study, we show that CC3 
has the potential to predict 5-FU response, where CC3 not only upregulates in response to 
treatment, it also predisposes the cells to drug-induced death. 
Although the synergistic effect of CC3 and 5-FU led to an increase in sub-G1 phase, we 
cannot exclude the possibility that increase death was due to reduced proliferation as 
shown by increased G1-S phase arrest (Table 3.4). We did not find a significant G1-S 
phase arrest in CC3 over-expression alone. However, in gastric cell lines, an over-
expression of CC3 reduced Cyclin-D1 and increased p27 expression(Li, Zhang et al. 
2009). It would be interesting to investigate cell cycle regulators in 5-FU treated and CC3 







































CC3 5-FU + 
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Our studies of CC3 in clinical samples, its putative mechanism of action and its role upon 
5-FU treatment have shown that CC3 acts as a tumor suppressor in colorectal cancer and 
has prognostic significance as well as predictive significance in 5-FU response. Due to its 
potential translational relevance, it was also beneficial to elucidate how CC3 was 
regulated. Since we and others have found no mutation in CC3 clinical samples and cell 
lines, we focused our research in epigenetic modulation of CC3.  
 
Even though our methylation studies did not include tissue specimens, it has been 
reported that the tumor-type specific CpG island hypermethylation profile is still 
maintained in the long-established cell lines(Smiraglia, Rush et al. 2001; Paz, Fraga et al. 
2003). This shows that colon cancer cell lines are in general relevant in vitro models, 
comparable with the in vivo situation(Lind, Thorstensen et al. 2004).  Using 
bioinformatics tools,  a CpG island was found in the CC3 promoter. In both bisulfite 
sequencing and methylation specific PCR, we observe a correlation between high 
promoter methylation with a low CC3 expression. The presence methylation in CC3 CpG 
island in our work, as well as in hepatocellular carcinoma(Lu, Ma et al. 2008), together 
with its putative tumor suppressive role in cancer makes it an even more attractive 
candidate to evaluate its putative clinical usefulness as a diagnostic marker of disease. 
 
Furthermore, we used a pharmacological
 
reactivation approach to show that CC3 was 
upregulated
 
following 5-Aza-dC treatment in Colo320 cell lines. We recognize that 5-
Aza-dC, a nucleoside anti-metabolite and a potent inhibitor of DNA methyltransferase 1 
(Dnmt1), will have a global effect on other methylated genes(Soengas, Capodieci et al. 
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2001; Scott, Dong et al. 2006) and does not specifically target CC3. However, the results 
presented in this study demonstrate that exposure of Colo320 cell lines to 5-Aza-dC 
effectively demethylated the CpG regions within the CC3 promoter (Fig 3.22), leading to 
re-expression of CC3gene expression. We were also able to show that, upon silencing of 
CC3, the effect of 5-Aza-dC in enhancing chemotherapy sensitivity could be abolished 
(Fig 3.23), thus indicating that, as a consequence of CC3 promoter demethylation by 5-
Aza-dC, higher CC3 levels led to greater chemosensitivity and improvements in 
chemotherapy response. 
 
Since over-expression of CC3, in combination with 5-FU, appears to be efficacious in 
contributing to significantly increased apoptosis, our methylation work lead us to believe 
that the use of a demethylating agent which restores CC3 expression can also be an 
effective adjunct to chemotherapy in colorectal cancer and possibly other tumors with 
CC3 promoter hypermethylation. The clinical utility of 5-Aza-dC has been restricted to 
the treatment of leukemias and lymphomas(Karon, Sieger et al. 1973; Rivard, Momparler 
et al. 1981; Garcia-Manero, Kantarjian et al. 2006) but no significant effect has been 
demonstrated with solid tumors because of two major reasons: Firstly, its short half life 
prevents adequate accumulation deep within solid tumors, and secondly, high doses 
required to achieve clinical efficacy are associated with toxicity, like 
myelosuppression(Appleton, Mackay et al. 2007). However, our results suggest that a 
demethylating agent would function as a chemosensitizer, in part due to increased CC3 
expression,  and therefore, lower doses could be administered in combination with 5-FU 




The observation that CC3 was reduced in metastasized colorectal tumors (Fig 3.4) 
implies that CC3 may be involved in invasion and metastasis. HCT116 cells stably 
expressing CC3 had significantly reduced invasive capacity through ECM with a 
concomitant reduction in MMP1 (Fig 3.24), as compared to empty vector cells. The ECM 
is regarded as a barrier to tumor invasion and increased MMP activity enables greater 
ECM degradation, thereby facilitating tumor invasion and poor prognosis in colorectal 
cancers(Wagenaar-Miller, Gorden et al. 2004). MMPs are normally induced at the level 
of transcriptional activation(Ye, Eriksson et al. 1996) hence the regulation of MMP1 by 
CC3 may be a novel pathway in invasion. This finding where CC3 acts upstream of 
MMPs, is supported by two recent reports in hepatocellular carcinoma(Jiang, Pecha et al. 
2007) and lung carcinoma(Tong, Li et al. 2009). However, contrary to their findings, we 
did not see a significant difference in the motility of cells upon CC3 overexpression (Fig 
3.25).   
 
We had mainly focused our work on elucidating the role of CC3 as a tumor suppressor 
and its function in response to 5FU treatment. Another possible function of CC3 is its 
indirect anti-angiogenic role(NicAmhlaoibh and Shtivelman 2001), which may contribute 
to metastasis. Using a PCR array to investigate possible molecular actions of CC3, we 
found a number of angiogenic factors that were up-regulated. For example, Col18a1(also 
known as endostatin) is a known endothelial specific angiogenic inhibitor(Sim 1998), 
which can block the VEGF-VEGFR/Flk-1 pathway to inhibit the angiogenesis of colon 
tumor in nude mice(Jia, Dong et al. 2004). CC3 also down-regulated FGFR2, a receptor 
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which works with FGF (Fibroblast Growth Factor) to induce angiogenesis in 
tumors(Seghezzi, Patel et al. 1998). Hence, CC3 may work both as a tumor suppressor 




Concluding remarks and significance of study 
This is the first report where the role of CC3 in colorectal cancer progression has been 
studied. Using a novel CC3 monoclonal antibody, we have shown that CC3 is down-
regulated in more advanced, aggressive and metastatic colorectal cancer.  Furthermore, 
our pilot study in a panel of normal tissue shows that CC3 is ubiquitously expressed. This 
is also the first CC3 immunohistochemistry to be performed in a number of cancer 
subtypes compared with its normal tissues. More mechanistic work could focus on the 
regulation of CC3 in normal tissues and elucidate its physiological role. For example, it 
has been shown that TGF-β1 upregulates CC3(Lindfors, Halttunen et al. 2001) in small 
intestines. TGFβ 1 is a potent profibrogenic agent inducing collagen synthesis and 
regulating the balance between matrix-degrading matrix metalloproteinases (MMPs) and 
their inhibitors (TIMPs)(Di Sabatino, Jackson et al. 2009).  
 
Prior to this dissertation, much of the studies on CC3 have been focused on liver and lung 
cancers. In both cancers, CC3 was shown to act as a tumor suppressor by apoptotic and 
indirect anti-angiogenic mechanisms. It was proposed that CC3 may be involved in the 
mitochondrial pathway. Data obtained in our work have expanded the paradigm to 
colorectal cancer, where CC3 acts as a tumor suppressor to induce apoptosis, mainly by 
its regulation of Bcl-2 family members. In addition, it was shown previously in other 
cancers, that CC3 could sensitize cancer cells to apoptosis upon drug treatments. In this 
study, we demonstrated that 5-FU, together with CC3, induced localization of Bax to the 
mitochondria, which was linked to release of cytochrome c, hence leading to caspase 
activation and eventually cell death. Furthermore, specific methylated CpG sites have 
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been found within the CC3 promoter of colorectal cancer cell lines and higher expression 
of CC3 can be achieved with 5-Aza-2'deoxycytidine, leading to improved sensitivity to 5-
FU. Together, these results provide a promising rationale to explore and translate the 
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